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Menopause is a critical life-cycle transition for women, and is associated with 
osteoporosis and cardiovascular disease, leading causes of morbidity and mortality in US 
women. Efforts to curb symptoms of menopause include HRT and ERT, although 
conflicting evidence exists linking ERT and HRT with the risk of breast cancer. 
Physicians attitudes and preferred mode of treatment have been extensively studied, but 
with the increased utilization of nurse practitioners in the field, a new paradigm is being 
established. The overall goal of this study was to assess the nurse practitioners 
knowledge and attitudes about menopause, hormone replacement therapy and estrogen 
replacement therapy. More specifically, the objectives include to: 1) determine methods 
of patient education for menopausal women; 2) examine whether attitudes of menopause 
are predictors of preferred modes of treatment; and 3) determine whether demographic 
factors of nurse practitioners are predictors of preferred modes of treatment. 
A random selection of nurse practitioners from the state of Oregon were mailed a 
self-administered survey along with a stamped, addressed envelope. The questionnaire 
focused on knowledge of menopausal treatments, attitudes of menopause, continuing 
education in the menopause research, and methods of patient education. Follow-up 
Redacted for Privacysurveys were mailed to non-responders at two and four-week intervals following the first 
mailing. Response rate was 60% with a sample size of 192. 
Results describe the management practices of nurse practitioners and what 
influenced their prescribing and management practices. The influences included the 
following factors: perceptions about adequacy of formal education, continuing education 
and attitudes about menopause and managing menopause. Only 47.4% of the 
respondents felt that their formal education in menopause treatment and protocols was 
adequate. When asked how they treated women, a majority (64.6%) of the nurse 
practitioners depended on the women and her beliefs about menopause, HRT, and ERT 
when they considered how they cared for a menopausal women. Sixty-one percent were 
very likely to take time during a visit to discuss the changes a woman was going 
through, while 23.7% were most likely to answer questions if the client had any, 
otherwise leave the introduction of menopause to the client. When contraindications 
were present, all nurse practitioners were less likely to prescribe both ERT and HRT. A 
surprising trend was the high number of participants who were uncertain about how they 
would prescribe when contraindications were present. 
In summary, this study describes Oregon nurse practitioners attitudes about 
menopause, the perceived adequacy of their formal education, and likelihood of 
prescribing ERT and HRT. Since almost 50% of the nurse practitioners felt their 
education was inadequate in menopause, a systematic analysis of masters level nurse 
practitioner programs in the area of menopause and menopausal treatments is needed. 
Ideally, a nationwide survey comparing physicians and nurse practitioners prescribing 
practices would help quantify differences between the two types of health care providers. © Copyright by Teresa Mona Deprey 
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Chapter I 
Introduction 
Approximately four thousand American women begin menopause every day 
(Braus, 1993). Although menopause has historically been regarded as an inevitable, 
uncomfortable event that all women must face, it is not an event that should be given 
scant attention. If fact, menopause is perhaps the single most significant physical change 
that a woman will experience. 
Menopausal symptoms occur on a continuum and typically last from 3 to 5 
years. On average, a women goes through menopause between the ages of 48 and 55 
(Nachtigall, 1987). For many women, perimenopausal symptoms begin with an 
increasingly heavier menses, increased cramping, vasomotor instability (hot flashes or 
flushes), breast tenderness or enlargement, and vaginal atrophy. Menstrual cycles 
become shorter and menses become longer or irregular. Some women become 
depressed during menopause, though studies show that those women who have had 
previously depressive episodes tend to be at increased risk for depression during 
menopause (Hunter, 1990).  Other psychological symptoms which have been noted are 
nervousness, headaches, and insomnia (Bullock & Rosendahl, 1988). 
Along with possible psychological changes, specific endocrinological changes 
also occur during menopause. The sharp decrease in estrogen after menopause increases 
the rate of bone loss which can contribute to osteoporosis, especially if bone density of 
the woman is below one standard deviation of the mean (Riggs & Melton, 1992). 
Osteoporosis is a disease which is characterized by a thinning of the trabecular bone and 
effects over 20 million older Americans (Gambrell, 1992; Lindsay & Cosman, 1992). To 
be diagnosed with osteoporosis, one must have at least one fracture. Ninety percent of 2 
the people with osteoporosis are post-menopausal women and the health care costs 
linked to osteoporosis have become astronomical, with annual medical costs for covering 
fractures, pain, and deformity over $15 billion (Lufkin & Ory, 1989; Riggs & Melton, 
1992). 
In addition to estrogen-induced bone loss, women with decreased estrogen also 
face the risk of cardiovascular disease. Estrogen effects the lipid profile by increasing 
high density lipoproteins (HDL) and decreasing low density lipoproteins (LDL). A high 
HDL profile and low LDL profile have been linked to low risk of cardiovascular disease; 
therefore it is possible that estrogen has a protective effect during a woman's estrogen 
producing years (Lobo & Speroff, 1994). Since the late 1960's, physicians have been 
prescribing estrogen replacement therapy (ERT) to alleviate menopausal symptoms, 
decrease bone loss, and decrease the risk of cardiovascular disease. Menopausal 
symptoms, osteoporosis, and cardiovascular disease can decrease the quality and length 
of life for post-menopausal women and are major public health problems (Lufkin & Ory, 
1989; Prince et al., 1991). 
The theoretical basis for estrogen replacement therapy for menopausal women 
began during the 1930's and 1940's. When a group of 37 physicians began testing 
DES in the treatment of menopausal symptoms, they initiated the first step in the 
`medicalization' of menopause (Bell, 1987). Premarin was the first drug to be 
developed and placed on the market during World War II (Lewis, 1993). Over time, 
use of Premarin increased slowly. By the 1960's, Robert Wilson encouraged women to 
think of estrogen replacement therapy as a panacea in his book Feminine Forever 
(McCrea, 1983). Wilson's book introduced the use of estrogen to the general public 
and the many physicians who did not already know about estrogen's possible uses. In 
Feminine Forever, Wilson promised women, with the help of estrogen replacement 
therapy (ERT), that they would be free of aging and from being "condemned to witness 3 
the death of their womanhood" (cited in McCrea, p. 113). Since the publication of 
Feminine Forever, an increase in the prevalence of physicians prescribing ERT for 
treatment of menopausal symptoms occurred. 
The menopausal treatment protocols using estrogen generated significant 
controversy after a 1975 landmark case control study by Ziel and Finkle which linked 
ERT and endometrial cancer.  Ziel and Finkle (1975) found a risk ratio of 5.6 for 
endometrial cancer in the group of post menopausal women who were on ERT. The 
carcinogenic effect of estrogen on animals, particularly in the endometrium, had been 
found as early as 1933 (Ziel & Finkle, 1975).  Estrogen was found to stimulate 
hyperplasia and mitotic activity in the endometrium (Weiss, Szekely, & Austin, 1976). 
It's strong link to endometrial cancer became a concern because of the potential 
connection of estrogen and breast cancer. A persistent controversy surrounding ERT is 
the inconsistency among study results indicating whether estrogen has a beneficial or 
harmful effect on breast tissue (Henrich, 1992; Steinberg et al., 1991). 
The conflicting evidence of beneficial effects on bone mass and cholesterol levels 
and deleterious effects of breast and endometrial cancer, make the decision to use ERT 
confusing for both the practitioner and the patient. Since Ziel and Finkle's study (1975), 
the FDA Drug Bulletin update (1979) and the American College of Obstetricians and 
Gynecologists statement (1976), many health care provider reduced the number of 
prescriptions for ERT and changed the way they treated menopausal woman 
(Henderson, Ross, Lobo, Pike, & Mack, 1988). In order to decrease the potential side 
effects of ERT, health care providers have been prescribing estrogen with progestin to 
offset the deleterious effects of estrogen on the endometrium (Ross, Paganini-Hill, Roy, 
Chao, & Henderson, 1988). The combination of estrogen and progestin therapy is 
referred to as hormone replacement therapy (HRT). 4 
For the last sixteen years, health care providers have used hormone replacement 
therapy as standard care for the menopausal woman with an intact uterus, as 
recommended by the FDA and ACOG bulletins (Pas ley, Standfast, & Katz, 1984). 
Hormone replacement therapy was found to have similar beneficial effects on bone, 
though a still unresolved issue surrounding HRT is the magnitude of the effect of HRT 
on HDL and LDL's (Henderson, Ross, Lobo, Pike, & Mack, 1988; Lobo & Speroff, 
1994). This is an important unknown variable, considering that cardiovascular disease is 
the number one killer of women in the United States, particularly once a woman goes 
through menopause (Lufkin & Ory, 1989, Prince et al., 1991). 
Also during the last sixteen years the traditional health care provider most likely 
to counsel women about their treatment choices have been family and obstetric and 
gynecological physicians. Health care costs have risen dramatically in the last decade, 
necessitating more cost effective methods of delivering health care services. The 
emphasis on cost effective health care methods has necessitated a new paradigm for 
medicine. With the new paradigm, an increased use of nurse practitioners and physician 
assistants for primary and preventive health care. The use of a nurse practitioner instead 
of a physician is often cost effective and more practical. Nurse practitioners are often 
ideal for replacing the physician in many cases and are... 
... registered nurses who have advanced education and clinical training in 
a primary care field such as adult, family, geriatric, pediatric, psychiatric, 
school, or women's health. These providers are committed to health 
promotion and disease prevention; community-determined and 
community-based care; the use of appropriate health care technology; the 
use of appropriate health care personnel; and collaboration among health 
care professionals and between the health sector and other public 
sectors,....  In general, NP skills include the diagnosis and management 
of common acute illnesses, disease prevention, and the management of 
stable chronic illness. (Lancaster & Lancaster, 1993, p.5). 
The new paradigm for delivering health care services has developed slowly though there 
have been and still are many criticisms about the use of NP's in delivering services 5 
(Lancaster & Lancaster, 1993). One of the biggest criticisms has been the lack of a 
"standard level of educational preparation" (Lancaster & Lancaster, 1993, p. 6). 
Because of the increased use of nurse practitioners in traditional medical settings and the 
increase in the number of menopausal women, it is inevitable that more and more nurse 
practitioners will be treating menopausal woman. For this reason a close examination of 
the nature of nurse practitioners' methods of managing menopause is overdue. Also, 
since 1984, there has been conflicting evidence concerning ERT, HRT, and the increased 
risk of breast cancer (Bergkvist, Adami, Persson, Hoover, & Schairer, 1989; Coditz et 
al., 1995; Stanford et al., 1995; Steinberg et al., 1991). There has also been conflicting 
evidence about ERT, HRT, and the effects of both on cardiovascular disease from the 
Framingham study (Wilson, Garrison, & Caste lli, 1985). During the last decade, the 
United States has seen an increase in the use of nurse practitioners concomitant with 
conflicting and confusing data about ERT and HRT. 
Although physicians have previously been surveyed concerning their methods of 
managing menopause, little is known about nurse practitioners methods of managing 
menopause. To date, there have been no studies assessing the attitudes, knowledge and 
preferred mode of treatment of nurse practitioners on estrogen or hormone replacement 
therapy. 
The importance of reaching consensus on protocols for treating menopausal 
women is not only a clinical and philosophical issue for health care providers, but is also 
a public health issue. Menopausal women rely on the ability of practitioners to analyze 
and apply the current research on menopausal treatment modalities. The top level of 
health care experts in the government also expect physicians to counsel women about 
hormone replacement therapy. One objective of Healthy People 2000 clearly expects 
practitioners to have comprehensive knowledge on the subject of estrogen and hormone 
replacement therapy: 6 
OBJECTIVE 17.18: 
Increase to at least 90 percent the proportion of perimenopausal 
women who have been counseled about the benefits and risks of 
estrogen replacement therapy (combined with progestin, when 
appropriate) for prevention of osteoporosis. 
(Baseline data available in 1991). (DHHS, 1990, p. 466) 
Objective 17.18 directs health care providers to counselor perimenopausal 
women about ERT and HRT. Counseling should include the risks and benefits of both 
types of therapy. New research in the area of health care providers' preferred 
prescribing methods is necessary because of conflicting and confusing data that both 
health care providers and women use to make decisions surrounding health care. Five 
studies in the United States, one from Britain, and one from Finland, have surveyed 
physicians' prescribing practices and judgments about ERT and HRT, but not the 
frequency of counseling perimenopausal women about risks and benefits of ERT and 
HRT (Elstein et al., 1986; Hemminki et al., 1993; Holmes et al., 1987; Holzman et al., 
1984; Ross et al., 1988; Pas ley, Standfast, & Katz, 1984; Wilkes & Meade, 1991). The 
most recent study in the United States occurred in 1984 and was published in 1988 
(Ross et al., 1988). 
Statement of the Problem 
The purpose of this study was to survey nurse practitioners from the state of 
Oregon to determine their preferred mode of treatment of menopausal symptoms, 
knowledge and attitudes about menopause, HRT, and ERT and their relative comfort 
level with their past education. The practitioners attitudes towards the perimenopausal, 
menopausal, post menopausal woman, and their current knowledge about estrogen 
replacement therapy and hormone replacement therapy were evaluated through the use of 7 
a questionnaire.  Additionally, the nature and extent of continuing education used by 
practitioners to educate themselves about menopause was investigated. 
Significance of the Study 
This study was used to assess the knowledge and attitudes of nurse practitioners 
about menopause, HRT, and ERT. A baseline of knowledge and attitudes was compiled 
for the state of Oregon. The study will be able to provide clinics and other health care 
facilities with essential information useful in developing continuing education courses 
for nurse practitioners who are beginning to prescribe ERT and HRT. 
Objectives of the Study 
The study will address the following research objectives: 
1. To assess current methods of menopausal continuing education for nurse
 
practitioners.
 
2. To determine, in the nurse practitioner setting, methods of patient education for 
menopausal women. 
3. To determine if selected nurse practitioner demographic factors are associated with 
preferred modes of treatment. 
4. To determine if nurse practitioner attitudes about the efficacy and risks of treatment 
are associated of preferred modes of treatment. 
5 .  To determine if nurse practitioner attitudes about various aspects of menopause are 
associated with their preferred modes of treatment. 8 
Research Questions 
The following research questions will be investigated: 
1. What patient education methods do nurse practitioner's use for menopausal women? 
2. How likely are nurse practitioners to prescribe ERT and HRT? 
3 .  How adequate do nurse practitioners believe their formal education is about 
menopause? 
4. What are the methods nurse practitioners use to educate themselves about 
menopause? 
5 .	  What are the attitudes of nurse practitioners towards menopause? 
6. What is the association between nurse practitioners' attitudes about menopause and 
their likelihood of prescribing either HRT or ERT? 
7.	  Is there a difference between nurse practitioner's perceived adequacy of formal 
education in menopausal issues and likelihood of prescribing either ERT or HRT? 
8. Is there a difference between the following practitioner characteristics: 
sociodemographic setting, 
type of practice, 
years practicing in the medical field, 
and practitioner attitudes about menopause? 
Hypothesis 
1.	  There will be no differences between nurse practitioners attitudes and their preferred 
mode of menopausal treatment. 9 
2.	  There will be no differences between nurse practitioners perceived adequacy of 
menopausal training and their preferred mode of menopausal treatment. 
3.	  There will be no associations between the number of years a nurse practitioner has 
been in practice and their preferred mode of menopausal treatment. 
4.	  There will be no associations between age of nurse practitioner and their preferred 
mode of menopausal treatment. 
Operational Definitions 
Practitioner knowledge, prescribing practices, and attitudes were measured by the 
Menopausal Attitudes, Knowledge and Treatment (MAKAT) questionnaire which was 
developed by the author for the purpose of this study. 
Assumptions 
The following assumptions were made during the course of this study: 
1. There was the possibility of response error in the survey data due to the lower 
than expected return rate. 
2. The surveyed practitioners were a representative sample of nurse practitioners 
in the State of Oregon. 
Limitations 
The results of the study are limited by a less than 100% response rate of the 
sample population, which is common in mailed, self-administered questionnaires (NCI, 
1989). The study was conducted in the state of Oregon and every effort was made to 
obtain a representative sample of nurse practitioners and to insure high response rates, 
though respondents self-select to respond to the mailed questionnaire (NCI, 1989). 10 
Mailed self-administered questionnaires have certain limitations and may introduce bias 
into a study, which limits the possible conclusions of a study (NCI, 1989). Some 
practitioners may report practices which differ from their actual treatment practices 
because it may they may consider the answer an "acceptable" answer or lack of a sample 
"unacceptable" (Salant & Dillman, 1994, p. 18). Those that respond may be more 
interested in the topic, therefore, results may be positively biased. 
Delimitations 
This study was delimited to the following: 
1. Nurse practitioners registered in the state of Oregon. 
2. Nurse practitioners who registered as one of the following specialties: 
Women's Health Care, Adult, Family, Geriatric Nurse Practitioner or a 
Certified Nurse Midwife. 
3. Respondents' self-reports of their attitudes, prescribing practices, and 
knowledge. 11 
Definitions 
The following terms have been defined for use in this study: 
Attitude - is an organized predisposition to think, feel, perceive, and behave toward a 
referent or cognitive object (Kerlinger, 1973, p. 495). 
Cardiovascular Disease  diseases of the heart, blood vessels, and circulatory system. 
Disease Model or traditional medical model- defining and describing a health problem 
and set of symptoms in terms of a disease and treatment regime. 
Estrogen Replacement Therapy  prescribing estrogen before, during, or after menopause 
to relieve menopausal symptoms.
 
Hormone Replacement Therapy  prescribing estrogen and progestin before, during, or
 
after menopause to relieve menopausal symptoms.
 
Likert Scale - a set of items approximately equal in attitude value, to which subjects
 
respond in terms of degree of agreement or disagreement.
 
Menopause the cessation of ovarian function, resulting in permanent amenorrhea.
 
Usually a period of 12 months of amenorrhea assures cessation of ovarian function in 
older women. A definite diagnosis of menopause is necessarily retrospective (Greendale 
& Judd, 1993). 
Nurse Practitioner- a registered nurse who has advanced education and clinical training 
in a primary care field such as adult, family, geriatric, pediatric, psychiatric, school, or 
women's health 
Osteoporosis  a degenerative bone disorder characterized by increasingly porous bone 
and at least one bone fracture. 
Perimenopausal  a term used to describe the transitional phase of a woman's life 
occurring before and after the actual cessation of menstruation, when hormone 
production is declining. 12 
Post menopausal time period after menopause, generally six months after the last
 
period.
 
Practitioner - describing the nurse practitioner in this study.
 
Risk Ratio  defined as the ratio of the incidence rate of disease in the exposed group
 
divided by the corresponding incidence rate of disease in the non exposed group.
 
Vasomotor Instability  an instability in the nerves or centers controlling the size of blood
 
vessels, also known as hot flushes.
 13 
Chapter 2 
Review of the Literature 
This chapter will review the relevant literature concerning the conceptualization of 
menopause, the impact of menopause on women's health, and health care providers' 
management of menopause. First, menopause will be defined and the demographic 
trends of menopause in the United States will be explored. The second section of this 
review will discuss the history and early uses of estrogen replacement therapy.  In the 
third section the impact of menopause on women's health and the current methods of 
managing menopausal changes will be discussed. In the third section, research on 
health care providers' decision-making methods concerning the treatment of menopause 
will be reviewed. 
Definition of Menopause 
Menopause consists of the cessation of menstruation and a woman is considered 
"post menopausal" once a full year without menses has occurred (Bullock & Rosendahl, 
1988). Menopausal symptoms occur on a continuum and may last for 3 to 5 years. For 
many women perimenopausal symptoms begin with an increasingly heavier or lighter 
menses, increased cramping, vasomotor instability, breast tenderness or enlargement, 
and vaginal atrophy. Menstrual cycles become shorter and menses become longer or 
irregular. Some women become depressed, though studies show that women diagnosed 
with depression before menopause tend to be most likely to become depressed during 
menopause (Hunter, 1990). 
At one time the American Psychological Association's Diagnostic and Statistical 
Manual of Mental Disorders, listed involutional melancholia as a disease (Boston 
Women's Health Collective, 1994, p. 525).  Involution is defined in Webster's Ninth 14 
Collegiate Dictionary (1984) as "a decline marked by a decrease of bodily vigor and in 
women by the menopause" (p. 637).  The association between menopause and 
depression continues in our culture, though studies have found most women do not 
suffer from depression during menopause (Speroff, 1993). Other possible 
psychological symptoms associated with menopause are nervousness, headaches, and 
insomnia, though causal evidence is not available (Bullock & Rosendahl,  1988; 
Greendale & Judd, 1993). 
The above symptomology is attributed to the gradual process of ovarian failure 
which is manifested by a decline in the production of estrogen. The net effect of the 
decrease in the production of estrogen is the inability of the ovary to release eggs or to 
build up the endometrial wall necessary for fertilization to occur (Boston Women's 
Health Book Collective, 1992, p. 527). The sharp decrease in estrogen after menopause 
increases the rate of bone loss which can contribute to osteoporosis, especially if bone 
density of the woman is below one standard deviation of the mean (Riggs & Melton, 
1992). In addition to estrogen-induced bone loss, women with decreased estrogen also 
face the risk of cardiovascular disease. Estrogen effects the lipid profile by increasing 
high density lipoproteins (HDL) and decreasing low density lipoproteins (LDL). 
Because of the link of menopause with osteoporosis and cardiovascular disease, many 
physicians define menopause as a disease and treat it as such. 
Menopause: Deficiency Disease or Development Stage? 
While it may be simple to look at ovarian function and symptoms to define the 
onset of menopause, it becomes very difficult when the discussion of menopause is 
directed to the conceptualization of menopause. Many leading medical researchers in the 
field of menopause use the analogy of menopause and diabetes- a decline or deficiency in 
hormones that can put one at risk for many other health problems (Belchetz, 1994). In 15 
contrast, many social scientists, public health researchers, and feminists view menopause 
as a development stage. Whatever menopause may be, it is important to come to grips 
with the definition and language (disease vs. development stage) so that a common 
terminology can be used to describe the implications and health effects of menopause. 
An agreement on a common definition and language to describe menopause will help 
women understand menopause and challenges they may face during menopause. A 
closer look at the different philosophies is warranted. 
Throughout history menopause has had different connotations. In the 19th 
century Victorian age menopause was seen as "a sign of sin and decay" (McCrea, 1983, 
p. 111). During the Freudian age, menopause was seen as a neurosis (McCrea, 1983). 
Psychoanalysts of the era debated whether menopause was a time of disappointment and 
mortification or a time of "emancipation from sexual competition" (Swartzman & 
Leiblum, 1987). Since the advent and use of synthetic estrogen in the 1950's and 
1960's, menopause has been viewed by society, specifically the medical society, as an 
endocrine deficiency disease. 
McCrea, (1983), described four themes which are central to the definition of 
menopause as a deficiency disease: 
Women's potential and function are biologically destined. 
Women's worth is determined by fecundity and attractiveness. 
Rejection of the feminine role will bring physical and emotional havoc. 
Aging women are useless and repulsive (McCrea, 1983, p. 111). 
McCrea (1983) analyzed, through an extensive literature search, the 
medicalization of menopause and examined how the "disease or medical" model had been 
challenged inside and outside of the medical community. The medical model was first 
challenged outside the medical community by feminists. During the late 60's U.S. 
feminists defined the health care system as a "serious social problem." Most feminists 16 
charged the male dominated medical profession as practicing a form of social control. As 
with menstruation and birth, the medical profession defined menopause as a "condition" 
which then continued the prevailing ageism and sexism towards women in our culture. 
The medical model of menopause continues to be challenged from not only feminists but 
from women and men of different professional and ideological backgrounds. 
The first time the use of estrogen was challenged inside the medical community 
occurred in 1947 (McCrea, 1983). Dr. Saul Gusberg noted the histologic link between 
hyperplasia and adenocarcinoma in the female endometrium and found a significant 
increase in endometrial cancer among estrogen users (McCrea, 1983). The medical 
community ignored Dr. Gusberg. Interesting to note, some of the early research in the 
area of estrogen replacement thereapy did not even occur in women- sheep and men were 
used (Rebar, 1994; National Women's Health Report, 1995). The next challenge within 
the medical community occurred in 1975 in The New England Journal of Medicine. 
Two studies found a 4-10 times increase in endometrial cancer in women using 
exogenous estrogen (Smith, Prentice, Thompson, & Herrmann, 1975; Ziel & Finkle, 
1975). Since 1975, the medical profession has had to respond to the public about the 
possible effects of ERT on the endometrium. 
Since the medical challenges to ERT, the primary research in the area of 
endometrial cancer and ERT has focused on the effect of adding progesteron to estrogen 
for 10-12 days each cycle. Research in this area was positive. Rates of endometrial 
cancer for women on ERT with progesterone (HRT) are the same as in the general 
population (The Writing Group for PEPI Trial, 1996). Also, research in the 1980's has 
focused on what effect ERT and HRT has on lipids and overall cardiovascular mortality. 
Many physicians had noted benefits, but not until the early 1980's did research begin 
(except for research on sheep). 17 
In order to understand how our culture has arrived at it's current definition of 
menopause, the need for a historical perspective becomes timely. One researcher in the 
field has investigated the meaning of menopause in our society. MacPherson's (1993) 
contextual research found that since 1966, three general promises to women of 
menopausal age have permeated the literature concerning ERT and HRT. The first 
promise began with the publication of the book Feminine Forever (1966). Robert 
Wilson, author and gynecologist, was an early proponent of ERT and a catalyst in the 
medicalization of menopause. The first promise to women was that they would be eternal 
beauties and feminine if they took estrogen during menopause. This "promise" lasted 
until about 1975, when the second "promise" was given- that of a safe and symptom free 
menopause. 
In 1975, the epidemiological evidence that linked ERT to endometrial cancer was 
strong, therefore physicians and proponents of ERT researched and developed methods 
that were safe. By 1981, enough literature and studies had accumulated on menopause 
and HRT for the medical establishment to promise escape from chronic diseases, 
specifically osteoporosis, heart disease, ovarian cancer (if on HRT), and chronic vaginal 
atrophy and dysphoria. This was the third promise and it primarily responsible for most 
physicians prescribing ERT and HRT, so that women will be "free" of chronic diseases 
(MacPherson, 1993). 
Bell (1987) examined the intellectual roots of the medicalization of menopause 
and found three models which were developed to understand menopause: biological, 
psychological and environmental. Bell's research consists of an analysis of early articles 
about menopause published by 37 physicians, all of whom published in medical journals 
between 1938 and 1941 (Bell, 1987).  Bell explains: 18 
Medical specialists developed three models for understanding the 
causes (and cures) of menopausal complaints: biological, 
psychological and environmental. Most commonly, they studied 
biological changes and described menopause as a physiological 
process caused by cessation of ovarian function....Specialists also 
recognized that psychic and emotional disturbances formed an 
"important part of the menopausal syndrome". In other words, a 
woman's personality pattern could be the underlying cause of 
symptoms, instead of estrogen withdrawal....Infrequently, 
specialists identified the etiological role of environmental factors 
in producing menopausal symptoms... symptoms were 
"explainable more rationally as the result of the stress and strain 
resulting from the rearing of large families of children, or because 
of domestic, economic, or marital problems.." (Bell, 1987, p. 
538, 539). 
On the conceptual level, the medicalization of menopause occurred in the 1930's 
and the 1940's. Physicians had finally developed a treatment for menopause which was 
fairly inexpensive. In 1943, conjugated equine estrogen was developed and marketed 
under the brand name Premarin. But it wasn't until the 1960's that the medicalization of 
menopause became cemented with the publication of Feminine Forever by Robert Wilson 
(1966). Wilson was funded by the pharmaceutical industry ($1.3 million) to start his 
foundation. The Wilson Foundation promoted estrogen use and did so through the 
medical literature and the lay literature. Feminine Forever was widely read by the general 
public and made the case that all women should be given estrogens from puberty to grave 
(McCrea, 1983). By 1970, Premarin is one of the top four prescription drugs in the US 
(Worcester & Whatley, 1992). In 1975, the National Prescriptions Audit reported that 
over 28 million prescriptions for estrogen had been filled (Worcester & Whatley, 
1992). Then by 1976, major epidemiological studies (Mack et al., 1976; Smith, 
Prentice, Thompson, & Hellmann, 1975; Weiss, Szekely, & Austin, 1976; Zeil & 
Finkle, 1975) had found a causal link between ERT and endometrial cancer. 
Initially, the medicalization of menopause fed into many women's fear of losing 
their beauty and sexual appeal. By the mid 1980's, when pharmaceutical companies 
began an advertising blitz for estrogen replacement therapy in popular (versus medical) 19 
magazines, ERT and HRT were seen as ways to prolong life and prevent debilitating 
diseases. The companies used what some consider to be fear tactics by advertising their 
product as a cure for osteoporosis (Worcester & Whatley, 1992). When Wyeth-Ayerst 
began marketing Premarin and similar products through the media, less than 23% of all 
women knew about osteoporosis and how the disease was defined and diagnosed 
(Worcester & Whatley, 1992). Women are now highly educated about osteoporosis and 
the role estrogen can play, but few of the women have been educated about health 
promoting methods of disease prevention. 
A now common scenario which perpetuates the medical model of menopause 
begins with a perimenopausal woman having an irregular and/or heavy menstrual periods 
and making an appointment with her physician. In general, the physician will 
recommend a dilation and curettage (D and C). Often the irregular and heavy bleeding 
continues for a year or more and the woman goes to see her physician again, followed by 
yet another D and C. Typically, the heavy bleeding continues and the woman becomes 
anemic. Believing that there are no other options, the physician will then recommend a 
hysterectomy and oopherectomy. Often, once the woman has surgery, she becomes 
depressed because of the abrupt change in estrogen levels and is placed on estrogen and 
anti-depressants, maybe even tranquilizers to contain her mood (Boston Women's Health 
Collective, 1992, p. 529). What once was perceived as a natural change in hormones 
becomes a disease state to be reckoned with for the rest of a woman's life. 
Today's menopausal women is different than her grandmother or mother. She is 
highly educated, knowledgeable and assertive in comparison to her mother. 
Demographic Trends 
Every woman who lives past the age of 60 will go through menopause, whether 
naturally or surgically.  Currently, more than 40 million women are over the age of 50 in 20 
the United States, making this the fastest growing segment of the population. As 
increasing numbers of women reach menopausal age, the services which many clinics 
are offering will need to change to meet the needs of menopausal women. Many of these 
clinics will utilize nurse practitioners to deliver this menopausal care.  Others that already 
retain nurse practitioners as the primary health care provider have expanded their services 
to offer menopause counseling. One large non-profit national clinic, Planned 
Parenthood, has begun to educate and disseminate information about menopause to 
clients in order to increase the scope of its services and in order to better serve the needs 
of changing clientele (personal communication, Cheryl Long, April 8, 1994). 
With a large percentage of the population aging and increased costs,  the health 
care profession is overburdened.  The elderly population in the US is increasing rapidly, 
and is expected to represent 21 percent of the total population and to consume 45 percent 
of all health care expenditures by the year 2040 (Callahan, 1993). Physicians are not able 
to give quality care to every patient and women's health care problems are often 
"psychologized" and women are viewed as being more vulnerable to emotional problems 
(Rodeheaver & Datan, 1988). This is especially true for menopausal women. If 
anything, menopausal women often need special counseling to help them sort the 
controversies around treating their symptoms. 
Because of the strong need for health care workers with the expertise and time to 
counsel, the use of nurse practitioners and physician assistants has increased. 
Alternative care providers, such as NP's and physician assistants may not have extensive 
education in the field of menopause. The area of menopause and treatment of 
menopausal symptoms is changing rapidly. Health care providers who work with 
menopausal women need to stay abreast of the research in the area, but must also 
understand that each women has individual needs, risks and benefits to be assessed. 
Health care providers, in general, understand the need for more conclusive data around 21 
HRT and ERT, and they also understand the need to disseminate information in a 
organized manner. Once such organization is the North American Menopause Society. 
Since its inception in 1989, the North American Menopause Society has hosted annual 
meetings to disseminate "knowledge and the exchange of information about all aspects of 
menopause" (Randall, 1993, p. 1664). 
At a recent meeting, the results of a survey were released on how menopausal 
women educate themselves about menopause. For the most part, menopausal women 
seek health care providers when menopausal symptoms disrupt their lives, and in turn, 
health care providers are expected by society and their professional organizations to keep 
up with recent medical literature governing menopause. In the sample of women 
surveyed, only 36% of the women received menopausal information from their 
physicians and the remaining 64% received their information from magazines, journals, 
books, television, or peers (Randall, 1993). The quality and reliability of much of this 
lay information raises critical questions about the efficacy of informal information 
channels. Negative attitudes about menopause in American culture is common in sitcoms 
and a negative connotation is often implied. Because of the media bias surrounding 
menopause, many people have incorrect information about this stage in a woman's life. 
Instead of informal and lay sources being the primary source of information, materials 
and information presented to women by trained professionals would be much preferred. 
At the 1992 annual meeting of the North American Menopause Society, Dr. Wulf Utian, 
founding president of the Society, stated: "The foremost challenge ahead is to educate 
physicians about the specialized care that is needed in treating the problems and 
maintaining the health of women as they enter the approximate final third of their lives 
(p. 2485, Slolnick, 1992)." For the millions of women who will be going through 
menopause in the next 5 years, nonbiased and non judgmental information about the 
impact of menopause on a woman's health must to be disseminated. The most 22 
appropriate person to do this is the health care provider and perhaps the most appropriate 
channel is through lay sources. 
Impact of Menopause on Women's Health 
Many of the stereotypical images of what menopause does to a woman can be 
very misleading. Robert Wilson, in his book Feminine Forever (1966) was instrumental 
in propagating false images of menopause and it's impact on women and their health. 
According to Wilson, women who went through menopause could expect to have a 
myriad of problems such as, hot flashes, osteoporosis, vaginal atrophy, sagging and 
shrinking breasts, wrinkles, absent-mindedness, irritability, frigidity, depression, 
alcoholism, and even suicide (Wilson, 1966). All of these problems mentioned by 
Wilson could, of course, be allayed by estrogen replacement therapy. Not only did 
Wilson mention the effect of menopause on the woman, but the impact on her partner 
and children was also very serious. Since Feminine Forever was published the image of 
the menopausal woman has improved. 
Menopause can slowly, almost imperceptibly change a woman, with barely any 
disruption to her life, or menopause can drastically disrupt a woman's life. Changes in 
the menstrual flow, such as heavy bleeding often known as flooding, often limit a 
woman to staying home one or two times during her menstrual cycle. For some women, 
the changes in the menstrual flow are small or their menstrual flow decreases. Also, 
sleep deprivation due to hot flashes can often cause large mood swings and depression. 
Menopause can cause both acute and chronic changes in a woman. 
Acute Menopausal Changes 
Acute problems can reduce the quality of life for many woman, though they 
generally last a month or so. A working women with hot flashes during the night may 23 
have a difficult time making up lost sleep. The first time women seek care for 
menopausal symptoms, it is for the acute changes such as hot flashes and vaginal 
atrophy and infections. Care seeking women are often not really aware of the possible 
chronic changes that occur during menopause. Those women that seek help for acute 
changes, the majority of health care providers are concerned with the chronic changes 
that menopause can have on a woman, such as cardiovascular disease and osteoporosis 
(Rothert et al., 1990). 
Hot flashes 
One of the most common acute symptoms during menopause is the hot flash. 
Hot flashes or flushes often start prior to menopause, when menstrual periods become 
irregular. Blood vessels dilate and constrict irregularly when a women is going through 
a hot flash. The hot flash is often experienced as warmth in the face, neck and chest. 
Generally, hot flashes last for three to six minutes and during this time a woman may 
experience profuse sweating and increased heartbeat. 
In a recent survey by the North American Menopause Society, over 75% of the 
women mentioned that hot flashes were a symptom in perimenopause (Randall, 1993). 
Some cross sectional surveys have found that 70% of women experience a hot flush 
(McKinley & Jefferys, 1974). On the other hand, longitudinal studies which follow 
menopausal women found that only 40-58% of women had a hot flash during the final 2 
years of their menstruation (Greendale & Judd, 1993). For many women the largest 
problem a hot flash causes is a lack of sleep, which for some, can be particularly 
debilitating during the day. 
Urogenital Tract 
Estrogen keeps the mucous membranes elastic and healthy, therefore the decrease 
in estrogen will have an impact on all mucous membranes. The lower urinary and genital 24 
tract both have estrogen receptors, so when menopause begins, decreased estrogen 
levels in the body effects the lower urinary and genital tract. Changes in the urethra and 
periurethral tissues occur, as well as loss of pelvic tone, which can effect continence 
(Greendale & Judd, 1993). Low estrogen, hypoestrogenemia, is also associated with 
changes in the epithelial tissues of the lower genital tract. Atrophic vaginitis or vaginal 
atrophy often occurs around and after menopause. Symptoms of atrophic vaginitis 
include thinning of the vaginal walls, a loss of elasticity, flattening out of the ridges of 
the vagina, foreshortening and narrowing of the vagina, and increased drying and itching 
in the vagina (Boston Women's Health Collective, 1992, p. 534). The low estrogen state 
of the vagina can also effect the pH of the vagina, predisposing one to bacterial 
vaginosis. 
Vaginal estrogen creams are often used and relieve women of symptoms of 
atrophic vaginitis and lower urinary tract atrophy. Oral estrogen and topical estrogen 
creams, in combination with phenylpropanolamine, can also reduce recurrence of 
changes in the urinary tract (Raz & Stamm, 1993). 
Chronic Menopausal Changes 
Osteoporosis 
Approximately 1.3 million osteoporotic fractures occur each year and over 1.5% 
of the women who develop a hip fracture die from the fracture (Lobo, 1994; U. S. 
Preventive Services Task Force, 1990). Certain risk factors have been associated with 
osteoporosis such as, advanced age, female gender, Caucasian or Asian race, slight 
build, bilateral oophorectomy (both ovaries removed) prior to menopause, and smoking 
and alcohol abuse. Elderly women are the most common of all osteoporotic patients, of 
which the majority are postmenopausal. Over 25% of all women present with 25 
osteoporosis, but many more women are put on ERT and become reliant on physicians 
and screenings for breast, endometrial, and cervical cancers (MacPherson, 1993). 
Osteoporosis is clinically characterized by "loss of bone from trabecular bone and 
cortical bone" and fractures (Lufkin & Ory, 1989, p. 205). Estrogen receptors have 
been found in osteogenic cells, along with progestin receptors. Estrogen has also been 
shown to reduce osteoclastic bone resorption which in turn slows the rate of bone loss 
(Lufkin & Ory, 1989). Once a woman becomes menopausal, her rate of bone loss 
increases due to an increase in bone resorption. Numerous studies have shown the 
positive effects of estrogen on bone resorption (Cauley et al., 1988; Johnston et al., 
1989; Prince et al., 1991). For a person to be diagnosed with osteoporosis, one must 
have a fracture. The lifetime risk of developing a hip fracture for a woman of 50 with no 
unusual risk factors is 15.3% (Lobo, 1994). 
Cardiovascular Disease 
Another beneficial component of estrogen is the effect it has on lipoproteins. 
Women after menopause have a increased risk of cardiovascular disease and coronary 
heart disease (Colditz et al., 1987; Matthews et al., 1989). Studies have found that the 
lifetime risk of a 50 year old menopausal woman developing cardiovascular disease is 
46.1% and death occurs in 31% of these women (Lobo, 1994). Recent studies have 
shown a decrease in coronary heart disease and cardiovascular disease in women who 
take estrogen after menopause (Barrett-Conner & Bush, 1991; Bush et al., 1987; Colditz 
et al., 1987; Matthew's et al., 1989). The Lipid Research Clinic study found that 
women who took estrogen after menopause had a 0.34 relative risk of cardiovascular 
disease deaths occurring as compared to menopausal women who did not take estrogen 
(Bush et al., 1987). Numerous studies in the field of ERT and cardiovascular disease 
have observed a reduction in risk of cardiovascular disease by 40% to 50% (Barrett­26 
Conner & Bush, 1991; Goddard, 1992; Goldman & Tosteson, 1991; Lobo & Speroff, 
1994). 
In the Nurses' Health Study, current users of estrogen had a decreased risk of 
CHD (RR of major CHD=0.56) while former users had a relative risk of 0.83 (Stampfer 
et al., 1991). The benefits of estrogen on serum lipids are responsible for the reduction 
in the risk of CHD. Estrogen increased HDLs while simultaneously decreasing LDLs. 
Oral estrogen use in the menopausal women is more effective that transdermal and 
vaginal estrogens due to metabolism differences (Walsh, Sciff & Rosner, 1991). 
Still under debate is whether HRT has similar positive effects on lipid profiles. 
Progestins attenuate the positive effects on HDL's but these changes are dependent on 
dose, duration, and type of progestin. The PEPI trial tested 3 different types of 
progestin: estrogen plus cyclic medroxyprogesterone acetate (MPA), estrogen plus daily 
MPA and estrogen plus micronized progesterone (MP). All formula decreased LDLs and 
fibrinogen and increased triglycerides, though MP increased HDL the most (The Writing 
Group for PEPI Trial, 1995). 
The impact of menopause on a woman can be instrumental in whether or not a 
woman seeks care. Acute symptoms, such as hot flashes, often bring the menopausal 
women to the health care provider. At this stage in the process of seeking care, a woman 
is likely to be counseled by the health care provider about the possible chronic changes 
that her body is going through. Current management practices by the practitioner need 
to be individualistic due to the individualistic nature of how women go through 
menopause. Unfortunately, this is often not the case and a common occurrence is for 
menopausal women to be given a prescription without being counseled on 
contraindications and side effects. 27 
Management of Menopausal Changes 
Health care providers use a number of different sources to formulate methods of 
managing health problems. One such guide is the Guide to Clinical Preventive Services, 
(1996) 2nd Edition by the United States Preventive Services Task Force which AHCPR 
also uses as their clinical recommendations. Recommendations for postmenopausal 
hormone prophylaxis include the following: 
Counseling all perimenopausal and postmenopausal women about 
the potential benefits and risks of hormone prophylaxis. There is 
insufficient evidence to recommend for or against hormone 
therapy for all postmenopausal women. Women should 
participate fully in the decision-making process, and individual 
decisions should be based on patient risk factors for disease, clear 
understanding of the probable benefits and risks or hormone 
therapy, and personal patient preferences (Guide to Clinical 
Preventive Services, p. 829). 
The main audience for the Guide to Clinical Preventive Services is primary care 
physicians, nurse practitioners and physician assistants. Another government document 
which helps gauge the nation's health is Healthy People 2000. Healthy People 2000 is a 
set of goals and objectives for the improving the nation's health.  Objective 17.18 states 
that "at least 90% of all perimenopausal women should be counseled about the risks and 
benefits of hormone replacement therapy" (DHHS, 1990, p. 466). Although health care 
providers are required to counsel menopausal women on hormone prophylaxis, it is 
questionable whether or not providers are complying. 
Greendale and Judd (1993) reviewed the use of ERT and HRT in the 
management of menopause. They also summarized symptoms and common clinical uses 
for ERT and HRT. The following conditions are cited: 28 
Hot Flushes
 
Atrophic urethritis
 
Stress incontinence
 
Sensory-urge incontinence
 
Atrophic vaginitis
 
Dysphoric mood
 
Dyspareunia
 
Decreased sexual motivation
 
Osteoporosis prevention
 
Cardiovascular disease prevention
 
Estrogen Replacement Therapy 
Estrogen was first used in 1929 in the treatment of menopause, primarily to 
relieve symptoms of menopause (Lewis, 1993). A form of synthetic estrogen was 
developed in 1938 and widespread use of this drug was begun as part of the research and 
clinical trials necessary for approval by the U. S. Food and Drug Administration. This 
drug, diethylstilbestrol (DES), was approved within three years of its synthesis, even 
with the widespread disagreement over DES's toxic effects (Bell, 1987). 
Diethylstilbestrol is now a known carcinogen in offspring of women who have taken it to 
reduce miscarriages (Bullock & Rosendahl, 1988). 
By 1943, Premarin, the most widely prescribed form of synthetic estrogen, was 
developed by Ayerst (Bell, 1987). As early as 1945, Premarin was being advertised in 
gynecological journals (Lewis, 1993). Estrogen replacement therapy had been in very 
limited use from 1929 on, but Wilson's book, Feminine Forever, was the catalyst 
which brought the concept of "treating" symptoms of menopause with ERT to lay 
persons (Lewis, 1993; McCrea, 1983). Wilson promised that ERT would treat 
menopause, allay aging, and avert 26 other symptoms--from osteoporosis to absent­
mindedness, to irritability and suicide (cited in McCrea, 1983). Estrogen replacement 29 
therapy did allay many unpleasant symptoms such as vasomotor instability and vaginal 
atrophy, but Wilson introduced estrogen as a panacea and youth pill for menopausal 
women. Through the late 1960's and early 1970's estrogen became one of the most 
prescribed drugs in America due primarily to the influence of Wilson's book; estrogen's 
market value also increased threefold (Lewis, 1993).  In 1975, the National 
Prescriptions Audit reported that over 28 million prescriptions for estrogen had been 
filled (Worcester & Whatley, 1992). 
By 1976, major epidemiological studies had found a causal link between ERT 
and endometrial cancer. Prescriptions of ERT plummeted, particularly in women with 
intact uteruses. For those women who had hysterectomies, ERT was still a "safe" and 
benign option. ERT is not for every women; there are contraindications to ERT besides 
having an intact uterus. 
Contraindications to ERT 
Contraindications to ERT are termed either 'Absolute' or 'Relative,' even though 
the experts are not in agreement about which is absolute. Absolute contraindications are 
those medical problems which prohibit the use of ERT for a patient. Relative 
contraindications are problems/diseases that the patient may have and that can have 
potential negative consequences if taking ERT. Table 1 and Table 2 list a compilation of 
contraindications by two experts in the field often diverges. Absolute contraindications 
are (Gambrell, 1992; Greendale & Judd, 1993): 30 
Table 2.1 Absolute contraindications to ERT. 
Undiagnosed vaginal bleeding
 
Suspected breast cancer
 
Suspected endometrial cancer
 
Active venous thrombosis
 
Suspected pregnancy
 
History of breast cancer*
 
History of endometrial cancer*
 
Malignant melanoma* 
*Under debate. 
Gambrell categorized undiagnosed vaginal bleeding and suspected endometrial 
cancer as 'relative' contraindications, unlike Greendale and Judd. Three 
contraindications are still under debate: history of breast cancer, history of endometrial 
cancer, and malignant melanoma. 
Contraindications to ERT are yet another confusing aspect of managing and 
treating menopause. Not only do experts disagree on when to use ERT, but they also 
have differences in opinion about contraindications to ERT. 
Table 2.2 Relative contraindications to ERT ** 
Uterine leimoyoma
 
Endometriosis
 
History of cholelithiasis
 
History of migraine
 
Hypertriglyceridemia
 
History of pregnancy related thrombosis
 
History of oral contraceptive-related thrombosis 
Liver disease. 
* *Patient should be specifically counseled about the potential negative consequences of taking estrogen if 
any of the relative contraindications are present. 31 
Complications with ERT 
Another reason why health care providers disagree upon ERT is the associated 
complications which may occur when taking ERT. Endometrial cancer is possibly the 
one complication with ERT that experts in the field agree upon.  Research in ERT and 
breast cancer has yielded inconclusive and confounding information. 
Endometrial Cancer 
From 1966 (publish date of Feminine Forever) until 1975, the use of estrogen in 
postmenopausal women increased. In 1975, two landmark studies were published in 
The New England Journal of Medicine which linked endometrial cancer and estrogen 
replacement therapy (Smith, Prentice, Thompson, & Herrmann, 1975; Ziel & Finkle, 
1975).). Smith et al., (1975), designed a retrospective case control study of endometrial 
cancer patients. They found the relative risk of endometrial cancer in the cases was 4.5 
times greater than that of the controls and with adjustments for age and year of diagnosis 
the relative risk increased to 7.5. Ziel and Finkle, (1975), also performed a case control 
study, using two controls for every subject. The risk ratio for those women using 
estrogen was 7.6 (Ziel & Finkle, 1975). The retrospective nature of the study decreased 
validity, but the increased incidence of endometrial cancer was so dramatic that 
methodology issues could not account for the total difference. 
In 1976, two further studies in The New England Journal of Medicine linking 
endometrial cancer with estrogen replacement therapy were published (Mack et al., 1976; 
Weiss, Szekely, & Austin, 1976). Physicians and women began to examine the risks 
and benefits of ERT in better detail.  Prescriptions for estrogen in the United States fell 
to from 28 million in 1975 to 15 million for the year 1979 (Lewis, 1993). To date, at 
least 20 epidemiological studies have found strong evidence that estrogen increases the 
relative risk of endometrial cancer anywhere from 1.1 to 12.0 times that of non estrogen 32 
users (Ernster et al., 1988; Goddard, 1992).  Appropriately, AHCPR Guidelines 
recommend that women who have not had a hysterectomy, progestin therapy or regular 
endometrial surveillance are recommended to reduce risk of endometrial cancer. 
Estrogen's carcinogenic effect on animals, particularly in the endometrium, had 
been detected as early as 1933 (Ziel & Finkle, 1975). Estrogen stimulates hyperplasia 
and mitotic activity in the endometrium (Weiss, Szekely, & Austin, 1976). After 1975, 
doctors began to add progestin to estrogen because it antagonizes the mitotic effects of 
estrogen on the endometrium. Instead of estrogen replacement therapy, the estrogen and 
progestin mix was named hormone replacement therapy (Ross, Paganini-Hill, Roy, 
Chao, & Henderson, 1988). The addition of progestin to ERT poses a interesting 
dilemma. Progestin decreases estrogen's beneficial effects on lipoprotein profiles. 
Progestin increases LDL's which negates, though how much is uncertain, estrogen's 
increase in HDL's (Lobo & Speroff, 1994). 
Breast Cancer 
Due to inconclusive empirical evidence, breast cancer is not reported as a 
complication to ERT in most medical journals and text books. It is mentioned here 
because of the controversy and inconclusive data surrounding ERT and breast cancer. 
The popular media is aware of this controversy and reports almost every study which 
links ERT or HRT with breast cancer. For this reason many menopausal women are 
confused and concerned about this issue and are hesitant to use ERT. 
At least 40 observational studies, and 6 meta-analyses of individual studies, have 
reviewed the association between ERT and breast cancer (Steinberg et al., 1991; 
Stanford et al., 1995; Bergvist, Adami, Persson, Hoover, & Schairer, 1989). Currently 
the literature suggests that women who take postmenopausal estrogen for long durations 
(10-15 years) have a slight increased risk (RR of 1.2-1.3) of breast cancer (Steinberg et 33 
al., 1991; Grady et al., 1992). The Nurses Health Study confirmed the increased risk. 
They found that the risk of breast cancer was increased only among current, long term 
users of hormones (> 5 years) (Colditz et al., 1995). The addition of progestin, (HRT), 
has not been shown to increase the risk of breast cancer. There have been modest 
increases found in three large cohort studies (Colditz et al., 1995; Schairer, et al., 1994; 
Persson, Yuen, & Berkvist, 1992) Case control studies found no increases in breast 
cancer (Stanford et al., 1995). The dilemma that both practitioners and menopausal 
women face is difficult. ERT has better CHD risk reduction that HRT, but ERT has an 
increased risk of endometrial cancer. Many women fear breast cancer and the ensuing 
loss of a breast (if mastectomy is chosen). For women, a cost benefit analysis, such as 
what physicians complete, is necessary. This type of analysis requires intense decision 
making, particularly for the women with a family history of breast cancer. 
In general, most practitioners complete a cost-benefit analysis when making 
decisions about ERT and HRT, for example: 
The average life expectancy of an American woman reaching 
menopause is approximately 30 years. Many of the most 
important causes of morbidity in older women (cardiovascular 
disease, osteoporosis, and various cancers) appear to be 
influenced by female hormones. Cardiovascular disease is the 
leading cause of morbidity and mortality in postmenopausal 
women: nearly half will develop coronary heart disease (CHD) in 
their lifetime, 30% will die from CHD (more than 230,000 
women per year), and 20% will have a stroke. An estimated 1.3 
million osteoporosis-related fractures occur each year in the U. 
S., nearly all in postmenopausal women. A 50-year-old white 
woman is estimated to have 16% chance of eventually suffering a 
hip fracture and a 32% risk of vertebral fracture. In comparison, 
the lifetime probability of developing endometrial cancer and 
breast cancer is only 2.6% and 10%, respectively, and the chance 
of dying from these cancers is only 0.3% and 3% (U. S. Guide to 
Clinical Preventive Services, 1996, p 829-830). 
Once an individual cost-benefit analysis for the patient is complete, the health care 
provider can recommend an appropriate therapy. The cost-benefit analysis may help the 34 
physician make a decision, but it may not allay the fears many women have concerning 
breast cancer. 
Hormone Replacement Therapy 
Once the link between estrogen replacement therapy and endometrial hyperplasia 
and carcinoma became causal (1975), prescriptions for ERT dropped. In the ensuing 
years since 1975, physicians and researchers have combined estrogen with synthetic 
progestogens. Progestogen prevents endometrial cancer in a "dose- and duration-
dependent fashion" (Belchetz, 1994). Timing and dosage is important as is the type of 
progestogen. Synthetic progestogens are used instead of natural occurring progesterone 
due to absorption problems and other side effects (Belchetz, 1994). 
Hormone replacement therapy is prescribed most often when a woman has an 
intact uterus. Progestogen has been added to estrogen in continuous and cyclic regime. 
If prescribed in the cyclic regime, progestogen should be taken at least 12 days a cycle in 
order to prevent the development of endometrial abnormalities (Belchetz, 1994). 
Contraindications to HRT 
Contraindications to HRT are distinct from ERT. Tables 3 and 4 list the absolute 
and relative contraindications, respectively. The variability of contraindications between 
ERT and HRT is apparent. Compliance to HRT is poor (Belchetz, 1989). One reason for 
poor compliance to HRT may be the complications and side effects associated with HRT. 35 
Table 2.3 Absolute contraindications to HRT 
Undiagnosed vaginal bleeding
 
Active estrogen-sensitive breast cancer
 
Estrogen-sensitive ovarian cancer
 
Pregnancy
 
Porphyria
 
Absolute contraindications to HRT include undiagnosed vaginal bleeding 
(symptom of endometrial carcinoma), active estrogen-sensitive breast cancer, estrogen-
sensitive ovarian cancer, pregnancy and porphyria. Porphyrias are disorders in which an 
enzyme defect leads to the accumulation and excretion of porphyrins (Bullock & 
Rosendahl, 1988). 
Table 2.4 Relative contraindications to HRT 
Thromboembolic disease, previous MI or stroke
 
Diabetic control may deteriorate
 
Active liver disease
 
Gallstones
 
Endometriosis
 
Deterioration of otosclerosis
 
Genetic disorders, e.g. porphyria, sickle cell anemia
 
History of herpes gestationis
 
Fibroids
 
Hypertension
 
(Jordan, 1994, p. 36) 36 
Complications with HRT 
Side effects of using HRT are one of the main reasons why many women do not 
comply with a prescription of HRT (Belchetz, 1989). One of the early side effects of 
HRT is withdrawal bleeding or return of the menstrual cycle for some women 
(Ferguson, Hoegh, & Johnson, 1989; Hemminki, Topo, Malin, & Kangas, 1993). 
Withdrawal bleeding occurs most frequently in the first few months of taking 
progestin. Other side effects of HRT are edema, bloating, weight gain, depression, 
headaches, premenstrual irritability, lower abdominal cramps, dysmenorrhea, and breast 
tenderness; all tend to limit compliance with HRT (Hahn, 1989; Vines, 1993) 
Alternative Medicinal Therapies 
Alternative medicinal therapies, also known as 'complementary' therapies, 
receive little or no mention in medical journals, though women and society have 
increased their use of alternative therapies considerably in recent years. Common 
alternative therapies mentioned in a popular self-help book (Our Bodies, Ourselves, 
1992) include relaxation techniques, massage, herbal medicines, vitamins, homeopathy, 
acupuncture, exercise, diet, herbal therapy, and various other techniques (Boston 
Women's Collective, 1992, p. 529). The extent to which menopausal women are 
seeking alternative medicine is unknown, though researchers have found that women 
who take ERT are less likely to favor natural approaches to dealing with menopause 
(Ferguson, Hoegh, & Johnson, 1989). 37 
Decision Making for the Menopausal Woman 
The statement, "The divergent opinions and recommendations to which women 
are exposed may compromise their ability to make informed decisions about ERT", 
describes best the dilemma that menopausal women face when educated about ERT and 
HRT (Logothetis, 1991). When making decisions about how to manage menopausal 
symptoms, a woman is often more likely to receive and seek information from 
nonphysician health care provider sources, such as magazines, journals, books, 
television, newspaper, and friends or family members (Randall, 1993). Health care 
providers need to take into consideration the methods and sources women use to make 
decisions about seeking treatment for menopause (Randall, 1993). Researchers have 
surveyed women about their attitudes toward menopause, self-care response in 
menopausal women, and judgment policies of women towards hormonal therapy in 
order to better understand women's experiences around menopause (Bernhard & 
Sheppard, 1993; Schmitt et al., 1991; Wilbur, Miller & Montgomery, 1995). Other 
areas of research include women's knowledge and attitudes towards estrogen 
replacement therapy (Ferguson, Hoegh, & Johnson, 1989). 
Ferguson (1989) found that women who take ERT are more likely to agree with 
the statement that "menopause is a medical condition." Some other factors that 
influenced the women in this study to take ERT were that their physician recommended 
ERT, ERT would stop hot flashes, and ERT would not cause cancer (Ferguson, Hoegh, 
& Johnson, 1989). Ferguson et al. encouraged to take more time and effort to counsel 
woman about ERT and HRT and to individualize the common risk-benefit ratio that is 
often used (Ferguson, Hoegh, & Johnson, 1989). 
There are numerous challenges to the menopausal woman who is trying to make 
a decision about ERT and HRT. First, a woman must find a health care provider whom 
they trust and respect. Second, the decision to use or not use ERT/HRT is often a 38 
decision she is encouraged to make, whether she is experiencing unpleasant symptoms 
or not.  Third, once they are counseled and educated about ERT/ HRT, they must 
process the incomplete and complex information and make a decision. Previous 
generations have had unquestioning faith in health care providers, but 1990's are being 
called the era of informed choice for medical consumers (Speroff, 1992). 
Women clearly want to participate in the decision making-process related to 
menopause. The current cohort of women reaching menopause wants information, 
involvement, control and choice regarding their care (Lockhart-Schnebly, 1993). 
Moreover, increasing evidence suggests that leaving decision-making to health care 
providers can create further problems with compliance, satisfaction and outcome 
(Kaplan, Greenfield & Ware, 1989). When women are asked who should make the 
decision about HRT, only small percentages indicate that the clinician should be the 
primary decision maker (Rothert et al., 1994; Lockhart-Schnebly, 1993). 
Many women consider the management of menopausal changes to be a personal 
decision; however, it is clear that the health care provider also has a critical role in 
providing information and presenting risks and benefits (Logothetis, 1991). Neither 
health care providers nor consumers in the health care system have prepared for the 
decisions facing women in their menopausal years (Rothert et al., 1994). 
A new clinical trial, the Women's Health Initiative, will help future generations of 
health care providers be more confident and comfortable in recommending a treatment 
modality for menopausal women. Over 25,000 women will be assigned to either 
placebo, estrogen alone (for women with prior hysterectomy only), or combined 
estrogen-progestin therapy. The Women's Health Initiative will include 45 clinical 
centers throughout the United States and will enroll women 50-79 years of age. This 
clinical trial is long overdue. End point results will be overall mortality, and the 
incidence and mortality associated with endometrial cancer, breast cancer and 39 
osteoporosis. Results should be available in 10 to 15 years (Hibbard & Hampson, 
1993). Until then, health care providers, such as nurse practitioners, will need to stay up 
to date and informed about ERT and HRT, while paying close attention to their patients 
needs, risks and symptoms. 
During the last sixteen years the traditional health care provider most likely to 
counsel women about their treatment choices have been family and obstetric and 
gynecological physicians. Health care costs have risen dramatically in the last decade, 
necessitating more cost effective methods of delivering health care services. The 
emphasis on cost effective health care methods has necessitated a new paradigm for 
medicine. With the new paradigm of care in the health system, providers are finding it 
necessary to listen closely and respond to the increasing needs and concerns of 
menopausal women. A traditional role for the nurse practitioner has been as a patient 
educator and medical history taker. These important skills have allowed the nurse 
practitioner to segue nicely into the role of health care provider for menopausal woman. 
Decision Making for Health Care Providers 
How do health care providers make their decisions about whether to prescribe 
ERT and HRT? For those providers who were in practice since the early 1970's , their 
decision whether to prescribe ERT changed drastically in 1975 and 1976. Pas ley, 
Standfast and Katz (1984) quantified those changes in the earliest study published on this 
topic. They examined, retrospectively, physician's prescribing practices for menopausal 
women through a survey administered to 717 physicians living in the Albany and 
Syracuse, New York area who were practicing either obstetrics-gynecology, internal 
medicine, or family practice. Eighty-one percent responded to the survey and a case 
study methodology was used to gather the data. Respondents were instructed to 
retrospectively compare their prescribing practices with "pre-endometrial carcinoma" 40 
days. One case study was labeled "Case History 1-1981", while another, with the exact 
same information about a patient, was labeled "Case History II- 1974". The physicians 
were expected to remember how they would have cared for a person in the same 
situation, but before the 1975 breakthrough research which linked ERT to endometrial 
cancer. The most significant prescribing difference between 1974 and 1981 was that 
physicians lowered the estrogen dosage in 1981, along with prescribing a shorter 
duration of therapy. The physicians were also asked which source of information made 
them most aware of the risk of endometrial cancer. The top sources of information were 
"reports in the literature, the FDA Drug Bulletin update, the statement by the American 
College of Obstetricians and Gynecologists and concerns expressed by patients" (Pas ley, 
Standfast, & Katz, p. 428). Though there were methodological flaws in this study, 
primarily the retrospective nature of the survey, the researchers were leaders in the field 
of qualifying how physicians make their decisions about prescribing ERT and HRT. 
Ross et al. (1984) completed a similar study in Los Angeles County area. They 
also used a case history approach and examined gynecologist past and present preferred 
prescribing practices. Gynecologists in 1985 were prescribing progestin at a much 
higher rate than they were 10 years ago and they also were prescribing a lower dose of 
estrogen (1.25 mg vs. 0.625 mg). In 1985, estrogen therapy prescriptions were a routine 
practice by nearly all the gynecologist (95%). 
Other researchers have hypothesized that gynecologists would be "less likely than 
family or other physicians to prescribe estrogen" because gynecologists are more likely 
to identify and be concerned about endometrial cancer where family practitioners would 
be more likely to see women with osteoporetic fractures (Holzman et al., 1984). This 
hypothesis is relevant to this body of research with a different type of health care 
provider, the nurse practitioner. Are women's health care nurse practitioners less likely 
than adult nurse practitioners to prescribe ERT? Also, Holzman et al. stated that "the 41 
physician's age, sex and medical specialty may also bear upon treatment philosophy" 
(Holzman et al., 1984). 
With these possible differences in mind, Holzman et al (1984) surveyed 25 
gynecologists and 25 family physicians about ERT and HRT prescribing decisions. 
They gave all physicians 30 written patient case descriptions and a questionnaire to 
complete. Four factors were "incorporated and systematically varied in each of the 30 
cases": (1) endometrial cancer risk, (2) osteoporosis risk, (3) vasomotor symptoms, and 
(4) current estrogen treatment status (on or not on estrogen). Each factor was varied as 
either standard, moderate or high in the 24 case studies. MANOVA analysis found two 
main effects which were statistically significant within the group of gynecologists: risk of 
endometrial cancer and the severity of vasomotor irregularities. When the cancer risk 
increased from standard to high, the overall probability of prescribing decreased from 
0.60 to 0.20. When the severity of vasomotor irregularities increased from standard to 
high, the probability of prescribing increased from 0.24 to 0.58. Results did not support 
the hypothesis of gynecologists being less likely than family physicians to prescribe 
estrogen. The health care providers were sensitive to two important issues: cancer risk 
and vasomotor irregularities. Osteoporotic risk was not a vital factor in physicians 
probability of prescribing ERT, though this research was completed over 13 years ago, 
before the was educated about osteoporosis. 
Hemminki et al. (1993), described the prescribing practices and attitudes of 
Finnish doctors and also described the opinions of the doctors concerning the benefits 
and risks of HRT. They surveyed a random sample of 100 male and 100 female 
gynecologist, 100 internist, 100 general practitioners, and 100 non-specialists. 
Response rate reached 74% after two reminders calls and overall analysis was completed 
by specialty. The physicians were given 2 case studies and were told to describe their 42 
method of dealing with the case studies. The case studies were written up in the 
terminology often used by physicians. 
Overall, the gynecologist were more likely to prescribe HRT than the other 
physicians. (Once again, this finding did not support Holzman's hypothesis that 
gynecologist were less likely to prescribe ERT.) On a positive note, life-style changes 
were mentioned as a course of action by all the physicians. The two most common life­
style changes in the response to the case studies were to quit smoking (50%) and review 
diet and exercise (34%). There was also a significant difference between the number of 
menopausal patients female physicians were treating compared to male physicians. 
Female physicians were treating more menopausal women than male physicians. As 
expected by the researchers, gynecologists were more likely to give hormonal treatment 
and more gynecologists were more likely to prescribe HRT for all women. 
The researchers also asked open-ended questions, in particular, if there were any 
problems the physicians noticed. From the physicians' perspective, the most common 
difficulty for a woman on HRT was the return of their menstrual period. Physicians 
found it difficult to convince women to continue taking HRT when their menstrual 
periods returned, and they also found it a problem in helping women with 
contraindications to HRT (Hemminki, Topo, Malin, & Kangas, 1993). 
A survey of general practitioners in Great Britain by Wilkes and Meade (1991) 
found that the physicians were prescribing HRT to an estimated 9% of their female 
patients aged 40 to 64 and many had increased the number of patients to whom they were 
prescribing. The main reason physicians were prescribing was to prevent osteoporosis, 
with the next most important reason being to prevent cardiovascular disease. Similar to 
previous research (Hemminki, Topo, Malin, & Kangas, 1993), Wilkes and Meade found 
that on average female physicians were treating 5 more menopausal women that male 
physicians. Most physicians prescribed estrogen plus progestin and women physicians 43 
(18%) favored transdermal preparations and vaginal creams more than male physicians 
(11%). Many physicians in this study were interested in participated in a clinical trial 
with estrogen replacement therapy and were also very concerned about the unresolved 
questions of clinical benefits and hazards for HRT. 
In Elstein et al. (1986) and Holmes et al. (1987) research, complex decision 
analytical models was developed to describe and contrast physicians' and women's 
decisions regarding estrogen replacement therapy. Researcher compared what was most 
important to the physicians and to menopausal women when they decided to prescribe or 
take ERT. Physicians felt that to women, relief of symptoms was more important than 
fracture prevention.  In actuality menopausal women on ERT rated fracture prevention 
more important than symptom relief (Holmes et al., 1987). This type of research is 
important, particularly since clinical trials are not expected to yield results for many 
years. As the authors state, 
Decision analytic models are illuminating in considering such 
problems because they allow the explicit qualification of expected 
mortality from all relevant factors, as well as patient preferences 
for the likely outcomes. Our analysis suggests that when 
considering ERT, perimenopausal women rate outcome fractures 
as more important than physicians estimate that they do. 
Perimenopausal women more frequently reported preferring 
premature death in surgery to a longer life with disability from a 
hip repair than physicians estimated they would (Holmes et al., 
1987, p. 182). 
Overall, the research in this field has emphasized physicians and was completed 
over 10 years ago. New research in the area of decision making about treating 
menopausal symptoms is needed, particularly in light of the long wait before results from 
the Women's Health Initiative are published. 44 
Summary 
In this chapter, the literature on estrogen and hormone replacement therapy was 
reviewed as was women's and physicians' decision making about ERT and HRT; and 
chronic and acute health changes which can occur in a woman during menopause. 
In summary, the health care providers most likely to counsel women about their 
treatment choices have been family and obstetric/gynecological physicians. A new 
paradigm for medicine is taking formation as the use of nurse practitioners and physician 
assistants increase. With recent rising health care costs and health care reform a major 
political issue, cost effective methods of delivering health care services are vital. The use 
of a nurse practitioner instead of a physician is often cost effective and more practical 
(Lancaster & Lancaster, 1993; Safreit, 1992). Nurse practitioners are being utilized 
more in the clinical setting and are prescribing more for menopausal women as the 
population of menopausal women increases. 
Menopause can effect a women in both a chronic and acute manner. Often times 
the women seeks the health care provider when hot flashes, urogenital dryness, or 
changes in the menstrual cycle occur. Physicians on the other hand are very concerned 
about the more chronic effects of menopause when the women in fact has come in about 
acute problems. This initial visit is a critical point in the health maintenance of a 
menopausal women. Education is vital for the menopausal woman since the chances are 
most of her information has been received from informal sources and much of may be 
incorrect or biased. 
Menopausal treatment is a confusing and conflicting area, one which many 
women and health care providers have a difficult time when making decisions. The 
contraindications, such as undiagnosed bleeding and liver disease, must be taken into 
consideration. Unfortunately, many researchers and practitioners are unsure about the 
effect of ERT and HRT on breast tissue or even if women with a history of breast cancer 45 
should not take ERT and HRT. Women are often uncertain whether they are ideal 
candidates for estrogen replacement therapy or hormone replacement therapy.  In this 
capacity, health care providers play a critical role as patient educators. Health care 
providers are entrusted by menopausal women to help them make complex decisions in 
the area. With nurse practitioners utilized more than ever, this research is timely in it's 
evaluation of nurse practitioners' attitudes towards menopause, likelihood of treatment 
with ERT and HRT, and knowledge of contraindications to ERT and HRT. 46 
Chapter 3 
Methods and Procedures 
Studies which report on the management of menopause with ERT and HRT often 
use different experimental designs, populations, doses of HRT or ERT, and statistical 
methods, which make interpretation of the results difficult and confusing. Certain 
studies have focused on the benefits of ERT on breast cancer; while others have 
focused on benefits of ERT on heart disease and osteoporosis. As a result of these 
inconsistencies, health care providers face numerous challenges in making optimal 
treatment choices for their patients. Knowing what to do, based on the current literature, 
may prove to be a daunting task.  Also, health care providers differ in preferred or most 
popular modes of treatment for menopausal care. 
Women entering their menopausal years look to their health care providers to help 
them understand the conflicting and confusing research surrounding HRT and ERT. 
They assume that their trusted health care providers are making treatment decisions based 
on the best research results available. Researchers have surveyed physicians concerning 
their decision making, judgments, and preferred prescribing practices around ERT and 
HRT, but have not looked at attitudes towards menopause (Elstein, et al., 1986; 
Hemminki, Topo, Malin & Kangas, 1993; Holmes, et al., 1987; Holzman, et al., 1984; 
Pas ley, Standfast, & Katz, 1984; Ross, Pagannini-Hill, Roy, Chao & Henderson, 1988; 
Wilkes & Meade, 1991) 
While physicians practices are largely known, little is known about the 
prescribing practice of other essential health care providers. With nurse practitioners 
being utilized more in the treatment of menopausal women, it is increasingly important 
that research in their decision making, judgments, and preferred prescribing practices 
around ERT and HRT is conducted. In order to assess the current preferred mode of 47 
treatment for menopausal symptoms, this study solicited information from a random 
sample of nurse practitioners through a self-administered questionnaire. The attitudes, 
knowledge, demographics variables, and descriptive information about the clinical 
setting itself were also assessed. 
This chapter describes the study sample and the questionnaire developed for this 
survey. The methods for administering and analyzing the questionnaire are also 
described. 
Subjects 
The subjects in this study consisted of practicing nurse practitioners licensed and 
registered with the Oregon Nurses Association. Since there are no studies which have 
examined nurse practitioners' attitudes and knowledge about menopause, or their 
preferred mode of treating menopause, this research project was designed to provide this 
critical information. In order to complete this study, human subjects approval was 
sought and obtained by the Institutional Review Board of Oregon State University. 
The study population, nurse practitioners, has been active in the health care field 
since 1965 (Shanks-Meile, Shipley, Collins, & Tacker, 1989). By the 1970's, the 
demand for nurse practitioners positions had increased, particularly in the field of 
primary care (Shanks-Meile et al., 1989).  Since those early years, nurse practitioners 
have increasingly been sought after, resulting in a significant need in clinical practice. 
The need for nurse practitioners has increased tremendously. It was estimated that in 
1992, 6,400 nurse practitioner positions were unfilled (Lancaster & Lancaster, 1993). 
Nurse practitioners are vital in the patient education portion of clinical practice, though 
rules and regulations for how nurse practitioners can function vary greatly on a state by 
state basis.  Oregon's nurse practitioners enjoy a broad scope of practice compared to 
their colleagues in other states (Office of Rural Health, 1991). For example, nurse 48 
practitioners in Oregon can prescribe (including controlled substances) independent of 
any required physician involvement, unlike practitioners in 34 other states. 
For the purpose of obtaining baseline data, nurse practitioners from the following 
subspecialties were surveyed: family, adult, women's health care, certified nurse 
midwife or geriatric health. At the time of the study there were 937 registered nurse 
practitioners in Oregon. One hundred and thirty-seven were certified nurse midwives 
while the remaining 800 specialized in either family, adult, women's health care, primary 
mental, pediatric, or geriatric health.  Fifty-one of the nurse practitioners were living in a 
state outside of Oregon and were therefore excluded from the study.  Two hundred and 
sixty-two nurse practitioners were either pediatric and primary mental health practitioners 
and thus were also excluded due to the low probability of treating and prescribing 
hormone therapy for menopausal women. Twenty-two of the mailing labels were 
duplicated because of having two specialties.  In all, 602 nurse practitioners and certified 
nurse midwives met criteria for inclusion. In order to achieve a Beta of .80 (p= .05, two 
tailed) a total population of 206 was necessary to find a small effect size of .20 within the 
randomized study sample. In order to attain a response rate of 206, 325 questionnaires 
were mailed. Out of the 325 questionnaires mailed, a total of 192 nurse practitioners 
responded to the questionnaire, for an overall response rate of 60%. 
Instrument 
The Menopausal Attitudes, Knowledge and Treatment (MAKAT) (see Appendix 
B) was used to measure the variables of attitude, knowledge and preferred mode of 
treatment. The questions assess the following: 
I.  Basic Demographics 
Four questions measured age, race, gender, marital status; 49 
II.  Sources of Continuing Education 
Eleven questions addressed sources of education, and likelihood of use of 
new treatment protocols; 
III.  Attitudinal Scale 
Thirteen questions evaluated practitioners attitudes and beliefs about 
menopause and menopausal treatment. 
IV.  Knowledge Scale 
Eighteen questions assessed knowledge of contraindications to ERT and 
HRT. 
V.  Practice setting and demographics 
Thirteen questions addressed practice setting, demographics of practice, 
specialty, education, and present work situation. 
Eleven items in the attitudinal scale of the MAKAT were from an attitudinal scale 
developed by Groeneveld et al. (1993). Groeneveld et al. developed the scale with items 
from Frick -Bruderls scale (1983), Leiblum and Swartman's (1986) Menopause Attitude 
Questionnaire (MAQ) and from Ferguson, Hoegh, and Johnson (1989). Groeneveld's 
scale has three clusters, the first is a disadvantage cluster, the 2nd is an advantage cluster 
and the third is a treatment cluster. Cronbach's a for the three clusters was 0.78, 0.65, 
and 0.59, respectively. Eleven of the demographic and practice questions were taken 
from a questionnaire developed by the State of Oregon Office of Rural Health and the 
Office of Health Policy. The Office of Rural Health developed the questionnaire and 
mailed it to all registered nurse practitioners in the state of Oregon. 
The MAKAT instrument was piloted with 22 nurse practitioners and nurses from 
the Oregon State University Health Center, the University of Oregon Health Center and 
from various practices within the Eugene area.  Two experts in menopausal research, 50 
Judith Hibbard, Ph.D. and Sarah Hampson, Ph.D., and some members of the 
researcher's graduate committee reviewed the questionnaire for content and construct 
validity, along with a specialist at OSU's Survey Research Center in the Statistics 
Department. 
Procedures 
The list of registered nurse practitioners in Oregon was purchased from the 
Oregon Nurses Association in Portland, Oregon. After power calculations were 
computed and a randomization of the study population was completed, the selected 
practitioners were mailed a survey along with a stamped, addressed return envelope. 
Each survey was identifiable through the use of a code number on the top right back of 
the questionnaire. The survey was compiled in a booklet format most recommended by 
survey experts (Dillman, 1978). A cover letter accompanied the survey indicating that 
the individuals have been selected to participate in a state-wide survey related to 
"assessing attitudes of nurse practitioners towards menopausal treatment". The code 
number allowed the researcher to perform follow-up contact to non responders. At two 
weeks, all non-responders were mailed another questionnaire. A third survey was sent 
to all non-responders four weeks after the first original mailing. 
Data Analysis 
Data used in the study were derived from the information provided on each self-
reported questionnaire. The results of the questionnaire were entered into a Dell Ultra 
Scan 450 DE/2. The results from MAKAT were analyzed using the statistical package 
SPSS for Windows for personal computers. Data collected from the questionnaire were 
nominal, ordinal, and interval in nature. Descriptive statistics were computed for all 51 
data. Contingency tables were analyzed to determine associations which include 
nominally scaled variables. The X2 statistic (alpha = .05, two tailed) was employed to 
identify statistically significant differences, while phi coefficient (2 x 2 tables) and 
Cramer's -\i statistics (tables greater than 2 x 2) was computed to determine practical 
significance. Mann-Whitney test was used to test differences between ordinal and 
nominal scaled variables. For associations between ordinally scaled variables the 
Spearman rank order correlation was employed, while the Pearson product moment 
correlation was used to examine relationships among interval scaled data. 52 
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Introduction 
Approximately four thousand American women begin menopause every day 
(Braus, 1993). Although menopause has historically been regarded as an inevitable, 
uncomfortable event that all women must face, it is not an event that should be given 
scant attention. In fact, menopause is perhaps the single most significant physical 
change that a woman will experience. 
Menopausal symptoms occur on a continuum, typically lasting from 3 to 5 years 
and often resulting in significant health changes. The most pronounced of these effects is 
the potentially devastating effects of osteoporosis. About 70% of fractures in persons 
aged 45 or older are related to osteoporosis and most of these fractures occur in 
postmenopausal women (USPSTF, 1996). 
Although osteoporosis poses significant risks for women, the threat of 
menopausally induced risks for cardiovascular diseases may be even more profound. 
Menopause is associated with several unfavorable changes in the lipid profile: an increase 
in total cholesterol levels, an increase in low-density lipoprotein (LDL) cholesterol levels, 
and a decrease in the protective high-density lipoprotein (HDL) cholesterol levels 
(Radford, 1994). 
Women facing elevated risks from menopause or menopausal treatment often face 
a seemingly insurmountable amount of contradictory information. Knowing which 
information source is most reliable poses yet another hurdle for women facing 
menopausal decisions. During the last sixteen years the traditional health care provider 
most likely to counsel women about their treatment choices has been family and 
obstetric/gynecological physicians. More recently, in an increased attempt to reduce 
health care costs, HMO's have expanded the utilization of nurse practitioners. The use of 
a nurse practitioner instead of a physician is often cost effective and more practical for 54 
HMO's, especially in situations which may warrant more patient interaction and could 
ellipse the allowed time for physician in practices with large case load demands. 
The new paradigm in which NP's deliver health care services in increasing 
numbers has developed slowly and continues to be controversial (Lancaster & Lancaster, 
1993). One of the biggest criticisms has been a concern over whether NP's are 
operating within the limits of their standard of practice. Additionally, many worry about 
a lack of a "standard level of educational preparation" (Lancaster & Lancaster, 1993, p. 
6). Because of the increased use of nurse practitioners in traditional medical settings and 
the increase in the number of menopausal women, it is inevitable that more and more 
nurse practitioners will be treating menopausal women. For this reason a close 
examination of the nature and extent of nurse practitioners' methods of managing 
menopause, is long overdue. 
The nurse practitioner and the physician both need to be appraised of new 
research in menopause management. Every month, research with conflicting information 
and confusing recommendations is published. The importance of reaching consensus on 
protocols for treating menopausal women is not only a clinical and philosophical issue 
for health care providers, but is also a public health issue. Menopausal women rely on 
the ability of practitioners to analyze and apply the current research on menopausal 
treatment modalities. Health care providers use a number of different sources to 
formulate methods of managing health problems. One such guide is the Guide to 
Clinical Preventive Services, (1996) 2nd Edition by the United States Preventive 
Services Task Force which AHCPR also uses as their clinical recommendations. 
Recommendations for postmenopausal hormone prophylaxis include the following: 55 
Counseling all perimenopausal and postmenopausal women about 
the potential benefits and risks of hormone prophylaxis. There is 
insufficient evidence to recommend for or against hormone 
therapy for all postmenopausal women. Women should 
participate fully in the decision-making process, and individual 
decisions should be based on patient risk factors for disease, clear 
understanding of the probable benefits and risks or hormone 
therapy, and personal patient preferences (Guide to Clinical 
Preventive Services, p.  829). 
The main audience for the Guide to Clinical Preventive Services is primary care 
physicians, nurse practitioners and physician assistants. Another government document 
which helps gauge the nation's health is Healthy People 2000. One objective of Healthy 
People 2000 clearly expects practitioners to have comprehensive knowledge on the 
subject of estrogen and hormone replacement therapy: 
OBJECTIVE 17.18: 
Increase to at least 90 percent the proportion of perimenopausal 
women who have been counseled about the benefits and risks of 
estrogen replacement therapy (combined with progestin, when 
appropriate) for prevention of osteoporosis. (DHHS, 1990, p. 
466) 
Objective 17.18 directs health care providers to counselor perimenopausal 
women about ERT and HRT. Counseling should include the risks and benefits of both 
types of therapy. New research in the area of health care providers' preferred 
prescribing methods is necessary because of conflicting and confusing data that both 
health care providers and women use to make decisions surrounding health care. 
Researchers have surveyed physicians concerning their decision making, judgments, and 
preferred prescribing practices around ERT and HRT (Elstein, et al., 1986; Hemrninki, 
Topo, Malin & Kangas, 1993; Holmes, et al., 1987; Holzman, et al., 1984; Pas ley, 
Standfast, & Katz, 1984; Ross, Pagannini-Hill, Roy, Chao & Henderson, 1988; Wilkes 
& Meade, 1991). While physician practices are largely known, little is known about the 
prescribing practice of other essential health care providers. With nurse practitioners 56 
playing an increasing role in the treatment of menopausal women, it is increasingly 
important that research on their attitudes, knowledge, and preferred prescribing practices 
of ERT and HRT is conducted. 
In order to assess the current preferred mode of treatment for menopausal 
symptoms, this study solicited information from a random sample of nurse practitioners 
through a self-administered questionnaire. The attitudes, demographics variables, and 
descriptive information about the clinical setting itself were also assessed. The research 
questions in this study were: 
1.  What is the likelihood of nurse practitioners prescribing ERT and HRT? 
2.  Is there a difference between the following practitioner characteristics: 
sociodemographic setting, type of practice, years practicing in the 
medical field, and practitioner attitudes about menopause? 
3.  What methods are nurse practitioners using in patient education for 
menopausal women? 
4.  How adequate did nurse practitioners believe that their formal education 
about menopause was? 
5.  From what sources do today's nurse practitioner derive much of their 
current information about menopause? 
Methods 
The subjects in this study consisted of practicing nurse practitioners licensed and 
registered with the Oregon Nurses Association. Since there are no studies which have 
examined nurse practitioners' attitudes and knowledge about menopause, or their 
preferred mode of treating menopause, this research project is designed to provide this 
critical information. 57 
Nurse practitioners from the following specialties were surveyed: family, adult, 
women's health care, certified nurse midwife or geriatric health. At the time of the study 
there were 937 registered nurse practitioners in Oregon. One hundred and thirty-seven 
were certified nurse midwives while the remaining 800 specialized in six specialty areas: 
family, adult, women's health care, primary mental, pediatric, or geriatric health. Fifty-
one of the nurse practitioners were living in a state outside of Oregon and were therefore 
excluded from the study. Two hundred and sixty-two nurse practitioners were either 
pediatric and primary mental health practitioners and thus were also excluded due to the 
low probability of treating and prescribing hormone therapy for menopausal women. 
Twenty-two of the mailing labels were duplicated (the nurse practitioner had two 
specialties). In all, 602 nurse practitioners and certified nurse midwives met the criteria. 
In order to achieve a power of .80 (p= .05, two tailed) a minimum of 206 surveys were 
necessary to find a small effect size of .20. After 3 mailings, a total of 192 nurse 
practitioners responded to the questionnaire, for an overall response rate of 60%. 
Instrument 
The Menopausal Attitudes, Knowledge and Treatment (MAKAT) was used to 
measure the variables of attitude, knowledge and preferred mode of treatment.  The 
questions assessed the following: basic demographics (four questions measured age, 
race, gender, marital status); sources of continuing education (eleven questions 
addressed sources of education, and likelihood of use of new treatment protocols); 
attitudinal scale (thirteen questions evaluated practitioners attitudes and beliefs about 
menopause); and practice setting and demographics (thirteen questions addressed practice 
setting, demographics of practice, specialty, education, and present work situation). 
Eleven items in the attitudinal scale of the MAKAT were from an attitudinal scale 
developed by Groeneveld et al. (1993). Groeneveld et al. developed the scale with items 58 
from Frick-Bruderl's scale (1983), Leiblum and Swartman's (1986) Menopause Attitude 
Questionnaire (MAQ) and from Ferguson, Hoegh, and Johnson (1989).  Groeneveld's 
scale has three clusters, the first is a disadvantage cluster, the second is an advantage 
cluster and the third is a treatment cluster. Cronbach's alpha for the three clusters are 
0.78, 0.65, and 0.59, respectively. Eleven of the demographic and practice questions in 
the MAKAT were taken from a questionnaire developed by the State of Oregon Office of 
Rural Health and the Office of Health Policy. The authors developed questions about 
continuing education and patient education. 
Results 
Sociodemographic Characteristics 
One-hundred and ninety-two nurse practitioners responded to the MAKAT 
survey. Table 1 summarizes the characteristics of the participants. The majority 
(92.7%) were female and 94.3% Caucasian. Because gender and ethnicity had little 
variability, further analysis by these variables were unlikely to produce significant 
differences and associations. Just over 70% of all the participants were over 41 years 
old. Over 50% of the respondents were practicing in a city with a population of over 
50,000, although only one third of the clients were considered urban. The data infers 
that many patients come from rural areas to urban areas to seek care. 
Thirty-six percent of the participants were family nurse practitioners, 18.2% were 
adult nurse practitioners and 16.7% were women's health care nurse practitioners. 
Certified nurse midwives and geriatric nurse practitioners made up 16.7% and 3.6% of 
the participants, respectively. Eleven percent stated their specialty as geriatric or one of 
the following: emergency, sexually transmitted diseases, and anticoagulant. 59 
Table 4.1 Sociodemographic characteristics 
Female respondents  92.7%(n=192) 
Age of respondents 
25-40 years  28.6%  (n= 55) 
41-60 years  70.3%  (n=135) 
Size of town/city which is your primary practice site. 
0-9,999  20.8%  (n=40) 
10,000-50,000  22.4%  (n=43) 
more than 50,000  52.1%  (n=100) 
Client base description: 
Urban  32.8%  (n=63) 
Suburban  32.8%  (n=63) 
Rural  32.3%  (n=62) 
Numbers of years practicing as NP/CNM 
0-10 years  53.1%  (n=102) 
11-20 years  42.7%  (n=82) 
20+ years  3.1%  (n=6) 
Mean number of years practicing 9.8 years
WV.N.VMt.%. .*a 60 
Likelihood of prescribing ERT and HRT 
Perhaps the most important aspect of this research is the need to understand and 
qualify how likely nurse practitioners are to prescribe ERT and HRT. The NP's were 
questioned about how likely they would be to prescribe ERT and HRT, dependent on 
whether or not contraindications were present (4 questions in all). Table 2 displays 
frequencies of subject prescribing practices. As expected, when contraindications were 
present, nurse practitioners were less likely to prescribe both ERT and HRT. Nearly 7% 
would prescribe HRT when contraindications were present.  It was interesting to note 
that a high number (27.6% for ERT and 30.7% for HRT) of NP's were uncertain about 
whether they would prescribe when contraindications were present. As significant 
numbers of women may present with contraindications for ERT or HRT, it is important 
to note that this may be an important area of concern, reflective of the controversy 
surrounding ERT and HRT in general. 
Chi-square analysis among specialities found no significant differences, although 
trends were noticeable. One of the trends was that the women's health care nurse 
practitioners were more likely to have strong opinions about whether they would 
prescribe or not. Forty-six percent of the women's health care nurse practitioners stated 
they were very unlikely to prescribe ERT to a woman with contraindications, as 
compared to adult (32%) and family nurse practitioners (29%). Only 13% of the 
women's nurse practitioners were "unsure" about how they would prescribe when faced 
with this scenario compared to 38% of the adult and 35% of the family nurse 
practitioners. Over 50% of family, adult, and women's nurse practitioners were very 
likely to prescribe ERT when contraindications were not present. 61 
Table 4.2 Likelihood of NP's prescribing ERT/HRT with or without contraindications 
Statement  very  unlikely  unsure  likely  very 
unlikely  likely 
ERT to a symptomatic menopausal  7.3%  8.9%  8.3%  26.0%  43.2% 
client without contraindications?  n=14  n=17  n=16  n=50  n=83 
ERT to a symptomatic menopausal  30.2%  32.3%  27.6%  3.1%  0.5% 
client with contraindications?  n=58  n=62  n=53  n=6  n=1 
HRT to a symptomatic menopausal  2.6%  1.6%  4.2%  27.1%  57.8% 
client without contraindications?  n=5  n=3  n=8  n=52  n=111 
HRT to a symptomatic menopausal  20.8%  34.9%  30.7%  6.3%  0.5% 
client with contraindications?  n=40  n=67  n=59  n=12  n=1 62 
A majority (64.6%) of the nurse practitioners depended on the woman and her 
beliefs about menopause, HRT, and ERT when they considered how they cared for a 
menopausal women, while 14.3% of the nurse practitioners stated they followed HRT 
and ERT protocols which have been set by their national governing body (see Table 3). 
In summary, nurse practitioners for the most part depend on the menopausal woman's 
beliefs about menopause when considering whether to prescribe or not and many are 
unsure how they would prescribe when contraindications are present. 
Patient education has often been the task of the nurse in the clinic setting. Nurse 
practitioners were asked how likely they are to educate their menopausal client by 
utilizing selected educational methods. The practitioners were asked to state how likely 
they were to use each type of method. For each method, a five point Likert scale was 
used to gauge their likelihood of using a particular method in their practice setting.  Sixty-
one percent of the nurse practitioners were very likely to take time during a visit to 
discuss the changes a woman was going through, this was particularly true when the 
topic was initiated by the patient. Almost a quarter (23.7%) of all NP's were most likely 
to answer a clients questions about menopause, but they would not introduce the topic. 
Another 43% were unlikely to leave the introduction of menopause to the client. 
Approximately 12.2% of the sample stated they did not treat menopausal women. 
Having a patient educator talk to the client was the least likely way the nurse practitioners 
would educate their patients (92.3%), perhaps because most practices do not have patient 
educators and a nurse practitioner is often utilized in this role. 63 
Table 4.3 Method of caring for menopausal women by clinical specialty 
Method 
I follow HRT and ERT 
protocols which have been set 
by my national governing 
body. 
Family 
NP (n) 
8 
Adult 
NP 
(n) 
8 
Depends on the women and her 
beliefs about menopause, HRT, 
and ERT. 
53  21 
I recommend alternative 
medicine and do not recommend 
ERT or HRT often. 
0  0 
I do not treat menopausal 
women. 
3  2 
Other methods  4  2 
Women's 
NP (n) 
7 
CNM 
(n) 
2 
Other sub-
specialties 
(n) 
1 
Total 
(n) 
n=27 
(14.3%) 
20  20  6  n=122 
(64.6%) 
0  0  1  n=1 
(0.5%) 
2  5  8  n=23 
(12.2%) 
3  4  n=16 
(8.5%) 64 
Factors influencing nurse practitioners management  practices 
This study not only investigated how NP's prescribe, but also what influenced 
their prescribing practices.  Three factors appeared to have the greatest important effect 
on overall prescribing practices. These included: (1) perceptions about adequacy of 
formal education of NP's, (2) continuing education of NP's, and (3) NP's attitudes 
about menopause and managing menopause. 
Formal education: Perceived adequacy 
When respondents were asked whether they thought their formal education in 
menopause treatment and protocols was adequate or inadequate, nearly half (47.4%) 
responded that they did not think their formal education in this specialty area was 
adequate. Not surprisingly, family and adult specialty nurse practitioners were 
significantly more likely to rate their formal education inadequate than women's health 
care nurse practitioners (p=.00005). If the practitioners did not think their education was 
adequate, they were asked to briefly describe what was missing. 
Many respondents (n=103) did take the time to answer this open-ended question. 
For those who did respond, the range of answers was surprising. Some felt that they 
needed more clinical exposure to menopausal women, while others felt that the basic 
symptomology was not reviewed adequately. One geriatric NP stated, " ..we were 
taught about postmenopausal women and really nothing much about menopause". Most 
of the nurse practitioners mentioned that they lacked education about alternative 
therapies. Still other practitioners mentioned that basic information about the dosages of 
hormones to give was missing in their education. Some of the respondents received their 
education during the early seventies and mentioned that the focus of education at the time 
was women of childbearing age. 65 
Table 4.4 Elements of menopause received in formal education by specialty 
Element  Family 
NP(n) 
..... , 
Adult 
NP(n) 
Women's 
NP(n) 
CNM 
(n) 
Other 
specialties (n) 
Emotional changes of  51  21  31  18  15 
menopause* 
Dietary needs of  44  16  28  12  11 
menopause* 
Supplements for  49  20  29  11  13 
menopause 
Exercise for menopause 
Naturopathic remedies 
44 
10 
16 
5 
25 
5 
14 
2 
10 
3 
for menopause 
Symptomology of  65  26  32  24  16 
menopause* 
Contraindications to  61  24  31  17  16 
HRT* 
Contraindications to  64  24  31  18  16 
ERT* 
Bone loss during  64  26  30  19  20 
menoyause 
*p<. O1- Bonferroni Technique 66 
Table 4 describes, by clinical specialty, the elements of menopause 
education that nurse practitioners did receive during their formal education.  Chi-squared 
tests found significant differences in the data by clinical specialty. No one specialty was 
more likely to have received information about naturopathic remedies in their formal 
education. Women's health care nurse practitioners were significantly more likely to 
have received education in emotional changes, dietary needs, symptomology,  and 
contraindications to ERT and HRT. 
Continuing Education 
Continuing education plays a critical role for the practitioner who is treating 
menopausal women. New articles are released every month that either say ERT is linked 
to breast cancer or that ERT protects against breast cancer (Newcomb et al., 1995; 
Stanford et al., 1995). Health care providers must stay on top of the research.  This 
study investigated respondents likelihood of using certain methods of continuing 
education to educate themselves about menopause. 
This research attempted to determine which journals the nurse practitioners were 
likely to read if they wanted to learn new information about menopausal management. 
The MAKAT listed 13 different journals which had been mentioned most often by a 
sample of 22 nurses and nurse practitioners who pilot tested the survey. The respondents 
were asked "Which journals are you most inclined to read if you are interested in learning 
new information about menopausal management with HRT and ERT?" The most often 
viewed journals were, in descending order of popularity: The Nurse Practitioner, The 
Female Patient, American Journal of Nursing, NP Forum, Family Planning 
Perspectives, and the Journal of OB/GYN Nursing. 
Significant differences were found by clinical specialty in the type of journal 
read. Family nurse practitioners were more likely to read the American Journal of 67 
Nursing than any other clinical specialty, while all specialties were equally likely to 
read The Nurse Practitioner. Women's Health Care nurse practitioners were 
significantly (p=.007) more likely to read Family Planning Perspectives  and the Journal 
of OB/GYN Nursing for menopausal information than any other specialty. 
Respondents were also asked to indicate whether different methods of 
ascertaining information were used in making decisions about menopausal treatment. 
They were given six different methods; formal education, in-service training, 
workshops, national conferences, journals, and other nurse practitioners. The items 
respondents were all likely to use were journals (94.7%) and other nursepractitioners 
(88.5%). 
Along the same lines, the practitioners were asked "How likely are you to adopt 
new information about menopause which you have learned from each of the following": 
a journal, a conference, another CNM/NP, and a physician (4 separate questions). Table 
5 summarizes the results. 
The nurse practitioners seemed to adopt information most often from conferences 
(37.2%) and next to other nurse practitioners and certified nurse midwives (31.6%). 
Many were unsure about adopting information from a journal, though in the previous 
question they said they would use a journal in making decisions about menopausal 
treatment. 
Attitudes and beliefs about menopause 
The last set of questions from the MAKAT explored the attitudes of the nurse 
practitioners about menopause. The first statement, "Menopause is a metabolic and 
endocrine disorder", was strongly disagreed with by 39.6% of the respondents, while 
25% of the nurse practitioners agreed with the statement. Thirty-three percent of the 
respondents agreed with the statement, "Women expecting complaints in menopause will 68 
Table 4.5 Likelihood of adopting new information about menopause 
Source  very  unlikely  unsure  likely  very 
unlikely  likely 
learned from a journal  0.5%  2.7%  24.1%  52.9%  19.8% 
(n=1)  (n=5)  (n=45)  (n=99)  (n=37) 
learned from a  0  0.5%  4.3%  58.0%  37.2% 
conference  (n=1)  (n=8)  (n=109)  (n=70) 
learned from another  0.5%  1.1%  14.4%  52.4%  31.6% 
NP/CNM  (n=1)  (n=2)  (n=27)  (n=98)  (n=59) 
learned from an MD  0	  1.1%  15.4%  59.0%  24.5% 
(n=2)  (n=29)  (n=111)  (n=46) 69 
get them". Almost 50% of the participants agreed with the statement that 
menopausal symptoms such as hot flashes, depression, anxiety, and headaches should 
be treated with HRT. Along the same vein, 66% of the sample agreed that a women 
should consult her practitioner as soon as she suspects she is menopausal. 
Not surprisingly, 62% agreed that the benefits of HRT outweigh the risks. The 
typical menopausal woman in our society, often portrayed in the media, is viewed as a 
sexless person. It is heartening that 94% of the nurse practitioners disagreed with the 
statement "After menopause women have less sexual needs." After hot flashes, the 
most common "symptom" of menopause is the absence of menstruation. Many women 
view this as something to look forward to. The majority of the nurse practitioners in this 
study also viewed this as a positive change. Although, if a menopausal woman decides 
to use HRT (with progesterone) the chances are very high that she will continue to 
menstruate for a couple more years. Research has shown restarting menstruation a 
primary reason for poor compliance with HRT (Ferguson, Hoegh, & Johnson, 1989). 
On a positive note, many nurse practitioners feel that menopause can be both a time of 
personal growth (63%) and menopause brings positive aspects to the woman (83%). 
Table 6 summarizes the results. 
No significant associations were found among sociodemographic setting, type of 
practice the practitioner was in or years practicing in the medical field and attitudes about 
menopause. 70 
Table 4.6 Attitudes about menopause 
Statement 
Menopause is a metabolic 
and endocrine disorder. 
One starts to feel old in the 
climacteric. 
The benefits of HRT 
outweigh the risks. 
Menopause is a process of 
normal aging. 
Menopausal symptoms such 
as hot flashes, depression, 
anxiety, and headaches 
should be treated with HRT. 
One grows mature and more 
self-confident in menopause. 
After menopause women 
have less sexual needs. 
The absence of menstruation 
after menopause is a relief. 
During menopause one often 
feels unwell. 
Menopause brings many 
positive aspects. 
Menopause can be a time of 
personal growth for women. 
A women should consult her 
practitioner as soon as she 
suspects she is menopausal. 
Women expecting 
complaints in menopause 
will get them. 
strongly 
disagree 
39.6% 
(n=76) 
41.1% 
(n=19) 
2.1% 
(n=4) 
1.0% 
(n=2) 
1.6% 
(n=3) 
2.6% 
(n=5) 
43.2% 
(n=83) 
0.5% 
(n=1) 
13.0% 
(n=25) 
0 
0 
2.1% 
(n=4) 
5.7% 
(n=11) 
disagree 
31.3% 
(n=60) 
37.0% 
(n=71) 
5.7% 
(n=11) 
0 
16.7% 
(n=32) 
12.5% 
(n=24) 
50.5% 
(n=97) 
8.3% 
(n=16) 
44.8% 
(n=86) 
3.6% 
(n=7) 
0 
20.8% 
(n=40) 
27.6% 
(n=53) 
uncertain 
271%' 
(n=4) 
16.1% 
(n=31) 
29.2% 
(n=56) 
0 
32.8% 
(n=63) 
33.3% 
(n=64) 
4.7% 
(n=9) 
24.0% 
(n=46) 
22.9% 
(n=44) 
12.5% 
(n=24) 
1.0% 
(n=2) 
10.4% 
(n=20) 
27.6% 
(n=53) 
agree  strongly 
agree 
8.3% 
(n=29)  (n=16) 
3.1%  0 
(n=6) 
40.1%  21.9% 
(n=77)  (n=42) 
29.7%  69.3% 
(n=57)  (n=133) 
38.5%  8.9% 
(n=74)  (n=17) 
34.9%  13.5% 
(n=67)  (n=26) 
1.0%  0.5% 
(n=2)  (n=1) 
50.0%  15.1% 
(n=96)  (n=29) 
15.6%  0.5% 
(n=30)  (n=1) 
58.3%  25.0% 
(n=112)  (n=48) 
55.2%  43.8% 
(n=106)  (n=84) 
53.1%  13.0% 
(n=102)  (n=25) 
33.9%  2.6% 
(n=65)  (n=5) 71 
Summary 
The aim of this study was to assess and describe nurse practitioners' current 
preferred mode of treatment for menopausal symptoms. Identifying the sources of 
information nurse practitioners utilized when making decisions about menopausal 
treatments was also a goal of this research study. 
Nurse practitioners were more likely to prescribe HRT when contraindications 
were not present than they were to prescribe ERT (57% vs. 43%). It is possible that the 
main reason for this difference would be the strong association between ERT and 
endometrial cancer. ERT has been associated physiologically with endometrial cancer 
since at least 1976 (Weiss, Szekely, & Austin, 1976) and has been linked often with 
breast cancer (Grady et al., 1992; Stanford et. al, 1995; Steinberg et al., 1991). ERT 
may be perceived by NP's as a more controversial method of caring for menopausal 
women, though it is an acceptable therapy for a menopausal woman without a uterus. 
Women clearly want to participate in the decision-making process when 
presenting with menopause. The current cohort of women reaching menopause wants 
information, involvement, control and choice regarding their care. Moreover, mounting 
evidence suggests that leaving decision-making to health care providers can create further 
problems with compliance, satisfaction and outcomes (Kaplan, Greenfield & Ware, 
1989). Nurse practitioners seemed very attuned to this need. When NP's were asked 
about how they would treatment menopausal women, 64% depended on the woman and 
her beliefs about menopause, HRT, and ERT when they made this consideration. When 
women are asked who should make the decision about HRT, only small percentages 
indicate that the clinician should be the primary decision maker (Rothert et al., 1994; 
Lockhart-Schnebly, 1993). The majority of NP's feel that women should be a player in 
the menopausal decision making process. 72 
Adult and family nurse practitioners were significantly more dissatisfied 
than women's health care practitioners. One would expect that nurses who had received 
their training in the 70's and early 80's might be more dissatisfied with their formal 
education, because at the time research in the area was new, controversial, and required 
further research for validation. Surprising in light of the fact, when dissatisfaction was 
controlled for by age and number of years practicing, the differences were not 
significant. The open-ended question for explaining or listing what was missing in their 
education brought out a range of responses, which need to be further explored through 
qualitative research methods. 
When their formal education about menopause was investigated by content, 
significant differences occurred by specialty. Women's health care NP's were 
significantly more likely to have received education in all areas except supplements, 
exercise, bone loss and naturopathic remedies. WHCNP's were also not as likely to 
state that they thought their formal education was inadequate. This finding is what one 
would hope for and not surprising. What was interesting was the high numbers of 
NP's who did state there formal education was inadequate, particularly the family and 
adult NP's. 
Every NP's must receive continuing education units/credits to keep their 
certification. The nurse practitioners in this study were open to using different methods 
in continuing education about menopausal treatments.  NP's were most likely to adopt 
new information about menopause (and utilize the information) from another NP or a 
physician. This question was not open-ended, so all the possibilities that a nurse 
practitioner might use were not fully explored. Another means of education for both the 
nurse and patient could include the World Wide Web©. 73 
Attitudes and beliefs about menopause may bias the way a clinician manages 
menopause. Many physician believe that menopause is a disease and must be treated as 
such. NP's also felt that menopause is a metabolic and endocrine disorder (25%). 
In conclusion, health care providers are often the critical and pivotal person for a 
menopausal woman who is seeking relief from menopausal symptoms. The health care 
provider's attitudes towards menopause, whether a physician or a nurse practitioner, 
could be critical when transferred into practice. If a practitioner believes that menopause 
is a endocrinological disease, what is she likely to tell a menopausal woman? Is she 
more likely to suggest ERT and HRT? Previous studies of physicians have not looked 
into how attitudes about menopause reflect likelihood of prescribing ERT or HRT. 
Though research has shown that women who take ERT are more likely to believe that 
menopause is a disease (Ferguson, Hoegh, & Johnson, 1989), the majority of studies 
have quantified prescription habits and opinions concerning benefits and harms of 
hormones, while other studies have compared prescribing practices from time 1 to time 2 
(Hemminki, Topo, Malin, & Kangas, 1993; Pas ley, Standfast, & Katz, 1984; Ross, 
Paganini-Hill, Roy, Chao, & Henderson, 1988). This research has a different goal than 
previous work, but also seeks to spark further research into the prescribing habits of 
nurse practitioners and other health care providers. 
While this study did not find significant differences among clinical specialists 
who would possibly care for a menopausal woman, it did provide a first step in 
describing nurse practitioners attitudes towards menopause and management of 
menopause. Further research about health care providers preferred mode of treatment on 
a national level is necessary. Research that looks at the clinicians attitudes and decision-
making towards menopause, can help a menopausal woman choose her practitioner. On 
a practical level, once a better understanding of how health care providers attitudes effect 
their prescribing practices is reached, consumers will be able to choose health care 74 
providers with similar attitudes (through the use of physician report cards or 
computer kiosks such Massachusetts Blue Cross/Blue Shield kiosk). 
Once perceived inadequacies in masters level nursing programs are identified, 
educational specialists in the area could develop better curriculums and practicum 
programs nationwide. Further research in the area of effective patient education for the 
menopausal woman could also be completed. A research study may be able to correlate 
menopausal women's preferred mode of education with compliance and positive 
outcomes. This type of information could help clinical practices develop effective 
educational methods. 75 
Chapter 5 
Discussion, Conclusions, and Recommendations 
Discussion 
This chapter provides a discussion about the results of this study. It also reports 
conclusions as a result of the findings, and presents recommendations for further 
research. 
The aim of this study was to assess and describe nurse practitioners' current 
preferred mode of treatment for menopausal symptoms. Identifying the sources of 
information nurse practitioners utilized when making decisions about menopausal 
treatments was also a goal of this research study. 
Limitations of this study include the method of sampling. A simple random 
sample was used, where random sampling with replacement would have been ideal. At 
least 22 questionnaires were returned because either an incorrect address or the nurse 
practitioner had moved on. If replacement sampling had been used, a higher response 
rate may have been possible. Another limitation of the study was the timing of the mail 
out, which occurred at the start of the summer. Many people may have been on vacation 
during the time of the mailing. At least 20 of the respondents qualified their answers to 
certain questions. These 'qualifications' were impossible to quantify and leave the 
researcher with a hesitancy to include such data (though it was used). 
Another concern with the data set was the inclusion of certified nurse midwives. 
Certified nurse midwifery is a specialty area of nurse practitioners and they are often 
employed by obstetrics and gynecology practices. They are nurse practitioners who are 
trained in all areas of women's health, with a specialization in birthing. Though they 
specialize in one area of ob/gyn practices, they are often called upon in other areas of the 76 
reproductive tract, such as menopause symptomology. About20 percent of all CNM 
visits are for care outside the maternity cycle (Kraus, 1994). Also, with the changing 
demographics of our population and the need for more cost effective health care  (which 
nurse practitioners give), the inclusion of CNM's in this data set is justified. 
Likelihood of prescribing hormone and estrogen  replacement therapy 
Nurse practitioners were more likely to prescribe HRT when contraindications 
were not present than they were to prescribe ERT (57% vs. 43%). It is possible that the 
main reason for this difference would be the strong association between ERT and 
endometrial cancer. ERT has been associated physiologically with endometrial cancer 
since at least 1976 (Weiss, Szekely, & Austin, 1976) and has been linked often with 
breast cancer (Grady et al., 1992; Stanford et. al, 1995; Steinberg et al., 1991). ERT 
may be perceived by NP's as a more controversial method of caring for menopausal 
women, though it is an acceptable therapy for a menopausal woman without an uterus. 
Women's heath care nurse practitioners were more likely to prescribe both ERT and 
HRT and were less likely to be "unsure" of how they would prescribe.  Research with 
physicians has shown similar results, with gynecologists being more likely to prescribe 
HRT and ERT than internist or general practitioners (Hemminki, Topo, Malin, & 
Kangas, 1993; Pas ley, Standfast, & Katz, 1984). 
Factors influencing nurse practitioners prescribing practices 
This study not only investigated how NP's prescribe, but also what influenced 
their prescribing practices. Three factors appeared to have the greatest important effect 
on overall prescribing practices. These included: (1) perceptions about adequacy of 
formal education of NP's, (2) continuing education of NP's, and (3) NP's attitudes 
about menopause and managing menopause. 77 
Inadequacies in formal education 
Adult and family nurse practitioners were significantly more dissatisfied with 
their education than women's health care practitioners. Women's health care 
practitioners were less likely to be "unsure or uncertain" when answering questions, 
suggesting that their formal education was comprehensive in the field of menopause. 
One would expect that nurses who went to school in the 70's and early 80's 
might be more dissatisfied with their formal education, because at the time, research in 
the area was new, controversial, and required further research for validation. 
Suprisingly, when dissatisfaction was controlled for by age and number of years 
practicing, the differences were not significant. 
The open-ended question for explaining or listing what was missing in their 
education brought out a range of responses, which were further explored through 
qualitative research methods (see Appendix B for data). Exploration of the data did not 
find variability, though the adult and family nurse practitioner were less satisfied. All of 
the specialties were equally represented and most felt that little was included on the topic 
of alternative therapies in their formal education. Second, issuesd centering around HRT, 
such as protocol, complications, and risk vs benefit, were a major concern. Several 
respondents described their educaiton as having "a disease focus." Another common 
complaint from nurse practitioners was that they did not have enough clinical experience 
with menopausal women. 
When their formal education about menopause was investigated by certain 
elements of menopause education, significant differences occurred by specialty. 
Women's health care NP's were significantly more likely to have received education in 
all areas except supplements, exercise, bone loss and naturopathic remedies. Women's 
health care practitioners were also not as likely to state that their formal education was 
inadequate (19%). This finding is what one would hope for and not surprising. What 78 
was interesting was the high numbers of other NP's who did state there formal education 
was inadequate, particularly the family (40%) and adult NP's (71%). 
Continuing education 
Every NP must receive continuing education units or credits to retain their 
certification and continue employment. The nurse practitioners in this study were open to 
using different methods in continuing education about menopausal treatments. Nurse 
practitioners were most likely to adopt new information about menopause (and utilize the 
information) from another NP or a physician. This question was not open-ended, so all 
the possibilities that a nurse practitioner might use were not fully explored. Other means 
of education for both the nurse practitioner and patient could include the World Wide 
Web© and distance learning classes. 
Attitudes and beliefs about menopause 
Attitudes and beliefs about menopause may bias the way a clinician manages 
menopause. Many physician believe that menopause is a disease and must be treated as 
such. Some NP's also felt that menopause is a metabolic and endocrine disorder (25%), 
though they also felt that menopause is a process of normal aging (99%). Clearly, nurse 
practitioner are as confused about menopause as are many women. This lack of a concise 
and definitive attitude can have a grave effect on the menopausal women seeking 
treatment. Many researchers and feminists believe menopause, like childbirth, is being 
medicalized by the patriarchal health field (MacPherson, 1993; McCrea, 1983) and the 
medicalization is one more way that women are controlled through their bodies. Since 
the large majority of nurse practitioners are women (92.7% in this random study in 
Oregon), they are an ideal population in the medical field to help demystify menopause, 
without being seen as patriarchal and controlling. 79 
Conclusions 
Women clearly want to participate in the decision-making process when 
presenting with menopause. The current cohort of women reaching menopause wants 
information, involvement, control and choice regarding their care. Moreover, mounting 
evidence suggests that leaving decision-making to health care providers can create  further 
problems with compliance, satisfaction and outcomes (Kaplan, Greenfield & Ware, 
1989). Nurse practitioners in Oregon were very attuned to this need. When NP's were 
asked about how they would treatment menopausal women, 64% depended on the 
woman and her beliefs about menopause, HRT, and ERT when they made this 
consideration. When women are asked who should make the decision about HRT, only 
small percentages indicate that the clinician should be the primary decision maker 
(Rothert et al., 1994; Lockhart-Schnebly, 1993). The majority of NP's feel that women 
should be a player in the menopausal decision making process. 
In conclusion, health care providers are often the critical and pivotal person for a 
menopausal woman who is seeking relief from menopausal symptoms. The health care 
provider's attitudes towards menopause, whether a physician or a nurse practitioner, 
could be critical when transferred into practice. If a practitioner believes that menopause 
is a endocrinological disease, what is she likely to tell a menopausal woman? Is she 
more likely to suggest ERT and HRT?  Previous studies of physicians have not looked 
into how attitudes about menopause reflect likelihood of prescribing ERT or HRT. 
Though research has shown that women who take ERT are more likely to believe that 
menopause is a disease (Ferguson, Hoegh, & Johnson, 1989), the majority of studies 
have quantified prescription habits and opinions concerning benefits and harms of 
hormones, while other studies have compared prescribing practices from time 1 to time 2 
(Hemminki, Topo, Malin, & Kangas, 1993; Pas ley, Standfast, & Katz, 1984; Ross, 
Paganini-Hill, Roy, Chao, & Henderson, 1988). This research has a different goal than 80 
previous work, but also seeks to spark further research into the prescribing habits of 
nurse practitioners and other health care providers. (See additional results in Appendix 
Recommendations 
While this study did not find significant differences among clinical specialists 
who would possibly care for a menopausal woman, it did provide a first step in 
describing nurse practitioners attitudes towards menopause and management of 
menopause. Further research about health care providers prescribing practices on a 
national level is necessary. Research that looks at the clinicians attitudes and decision-
making towards menopause can assist a menopausal woman in choosing her practitioner. 
More complex statistical methods such as, generalized estimating equations or structural 
equation modeling, as well as other analytical decision making models could also utilize 
and explain practitioners prescribing practices. On a practical level, once a better 
understanding of how health care providers attitudes effect their prescribing practices is 
reached, consumers will be able to choose health care providers with similar attitudes 
(through the use of physician report cards or computer kiosks such Massachusetts Blue 
Cross/Blue Shield kiosk). 
This study also looked at perceived inadequacies in nursing programs. The two 
most common inadequacies stated were the lack of clinical experience with menopausal 
women and very little information on alternative therapies. Once perceived inadequacies 
in masters level nursing programs are identified on a national level, educational 
specialists in the area could develop better curriculums and practicum programs 
nationwide. It is also important to study the current trend of nurse practitioner 
employment in the health care system. How are nurse practitioners being utilized 
currently and how will they be utilized in the next century? A needs assessment as well 
as research in HMO's use of nurse practitioners is vital at this time. 81 
Also necessary is further research in the area of effective patient education for the 
menopausal woman. This body of work briefly reviewed how nurse practitioners 
educated menopausal women. Nurse practitioners were asked how likely they are to 
educate their menopausal client by utilizing selected educational methods. The 
practitioners were asked to state how likely they were to use each type of method. Sixty-
one percent of the nurse practitioners were very likely to take time during a visit to 
discuss the changes a woman was going through, this was particularly true when the 
topic was initiated by the patient. Almost a quarter (23.7%) of all NP's were most likely 
to answer a clients questions about menopause, but they would not introduce the topic. 
A worth while study would be to correlate menopausal women's preferred mode of 
education about menopause with compliance and positive outcomes. This type of 
information could help clinical practices develop effective educational methods for one of 
the largest growing populations in the United States. 
In the meantime, what should nurse practitioners and other health care providers 
who care for menopausal women do until results from the Women's Health Initiative are 
available? Probably the most important skill a health care provider can have during this 
time of uncertainty is the ability to listen to the perimenopausal and menopausal women 
who they see. Health care providers should follow AHCPR and Healthy People 2000 
objectives, both of which encourage health care providers to counsel all women and 
complete an individual risk-benefit analysis for every women. Practitioners should not 
wait for the perimenopausal woman to bring up the topic, but be more proactive in their 
methods of care. Educating women about side effects of HRT is also critical ; side effects 
are often the main reason why women are noncompliant and discontinue use of HRT. 82 
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The following questions will help us collect some general information
about your practice and your educational background. 
1.Please describe the town/city which is your primary practice site (circle one number 
1  Population less than 1,000  5  Population 5,000-9,999 
2  Population 1,000-1,999  6  Population 10,000-19,999 
3  Population 2,000-2,999  7  Population 20,000-50,000 
4  Population 3,000-4,999  8  Population more than 50,000 
2.  Would you describe the client base you serve as mostly (circle one number): 
1  Urban  2  Suburban  3  Rural 
3.  How long have you been practicing as a nurse practitioner or certified nurse 
midwife?  years 
4.  Approximately what percentage of your patients are women? (circle one
 
number)
 
1  LESS THAN 20%  4  61-80%
 
2  21-40%  5  81-100%
 
3  41-60%  6  NONE OF MY PATIENTS ARE
 
WOMEN 
5.  Of these women patients, how many are presenting with menopausal symptoms?
 
(circle one number)
 
1  LESS THAN 20%  4  61-80%
 
2  21-40%  5  81-100%
 
3  41-60%  6  NONE OF MY PATIENTS ARE
 
WOMEN 
6.  Does your primary place of employment financially support continuing education 
(more than $50 per year)?(circle one number) 
1  Yes  2  N o 
7.  How likely are you to educate your menopausal clients by  (circle one 
number for each) 
most  most 
unlikely  unlikely  unsure  likely  likely 
a. Taking time during a visit to discuss the changes, 
whether or not the client is aware of changes  1  2  3  4  5 
b.Answering questions if the client has any, otherwise 
leave the introduction of menopause to the client  1  2  3  4  5 
c.Educating through seminars for clients and 
educational materials which have been developed  1  2  3  4  5 
d.Having the patient educator talk to the client  1  2  3  4  5 
e.Other methods  1  2  3  4  5 94 
PLEASE USE THE FOLLOWING DEFINITIONS THROUGHOUT THE
 
SURVEY: 
Hormone Replacement Therapy  (HRT) = estrogen and progestin
 
replacement

Estrogen Replacement Therapy  (ERT) =  estrogen replacement
 
8.	  How would you describe the way you care for menopausal women? 
(circle the one which best applies to you) 
1I follow HRT and ERT protocols which have been set by my national governing body.
 
2 Depends on the women and her beliefs about menopause, HRT, and ERT.
 
3I recommend alternative medicine and do not recommend ERT or HRT often.
 
4 I do not treat menopausal women.
 
5 Other (please explain)
 
9.In which of the following elements of menopause did you receive formal education (ie, 
your university or certificate  program)? (circle one number for each) 
Yes  No 
a.Emotional changes of menopause  1  2 
b.Dietary needs of menopause  1  2 
c.Supplements for menopause  1  2 
d.Exercise for menopause  1  2 
e.Naturopathic remedies for menopause  1  2 
f.Symptomology of menopause  1  2 
g.Contraindications to HRT  1  2 
h.Contraindications to ERT  1  2 
i Bone loss during menopause  1  2 
10.	  What is your clinical specialty? 
11.	  When did you receive your degree?  19 
12.	  How did you obtain your NP or CNM education? (circle one number) 
1  Certificate program
 
2  Masters program
 
13.	  Where did you complete your training?
State 
14.	  Are you currently certified as an NP or CNM? 
1  NP- Yes  2  CNM- Yes 95 
15.	  How adequate was your formal education (ie, your university or certificate 
program) in menopause treatments or protocols? (circle one number) 
1  ADEQUATE 
2  INADEQUATE 
16.	  Are you currently working as an NP or CNM? 
1  YES  2  NO 
17.	  Which of the following best describes your present work situation? (circle o n e 
number) 
1  SOLO PRACTITIONER 
2  SINGLE SPECIALTY GROUP 
3  MULTI-SPECIALTY GROUP 
4  HMO 
5  CLINIC SETTING 
6  HOSPITAL SETTING 
7  STUDENT HEALTH CENTER 
8  OTHER (please specify) 
18.  Below are some nursing journals. Which journals are you most inclined to read 
if you are interested in learning new information about menopausal management with
HRT and ERT? (Circle yes or no and if yes please state the level.) 
If Yes: How? 
read read articles 
NO  YES  scan it  it all in specialty 
a.American Journal of Nursing  1  2  0  1  2  3 
b.The Nurse Practitioner  1  2  0  1  2  3 
c.Journal of Gerontological Nursing  1  2  1  2  3 
d.The Female Patient  1  2  0  1  2  3 
e.Family Planning Perspectives  1  2  0  1  2  3 
f.American Journal of Public Health  1  2  0  1  2  3 
g.Advances in Nursing Science 
h.Nursing Research 
1 
1 
2 
2 
0 
0 
1 
1 
2 
2 
3 
3 
I.Natural Health  1  2  0  1  2  3 
j.Journal of Advanced Nursing  1  2  0  1  2  3 
k.Nursing 
l.Journal OB\GYN Nursing 
1 
1 
2 
2 
0 
0 
1 
1 
2 
2 
3 
3 
m.NP Forum  1  2  0  1  2  3 
n. Other:  1  2  >>  1  2  3 
(please specify) 96 
19. From each source of information below, please indicate whether each of the 
following is a likely source of information you use in making decisions about 
menopasual treatment. (circle one number for each) 
very  very 
unlikely unlikely  not a  likely  likely 
source  source  source  source  source 
a.Formal Education (medical training  1  2  3  4  5 
b.In-Service Training  1  2  3  4  5 
c.Workshops  1  2  3  4  5 
d.National Conferences  1  2  3  4  5 
e.Journals  1  2  3  4  5 
f.Other Nurse Practitioners  1  2  3  4  5 
g.Other Sources (please specify)  1  2  3  4  5 
20. How likely are you to adopt new information about menopause  (circle one 
number for each) 
very very 
unlikely  unlikely unsure  likely  likely 
a.which You have learned from a journal?  1  2  3  4  5 
b.which You have learned from a conference?  1  2  3  4  5 
c.which You have learned from another NP/CNM? 1  2  3  4  5 
d.which You have learned from an MD?  1  2  3  4  5 
21. Which, if any, of the following conditions would prevent you from prescribing 
ERT? 
(circle one number for each of the following) 
most  most 
unlikely  unlikely  unsure  likely  likely 
a.History of breast cancer in family  1  2  3  4  5 
b.History of high blood pressure  1  2  3  4  5 
c.History of heart disease  1  2  3  4  5 
d.History of bone breaks  1  2  3  4  5 
e.History of varicose veins  1  2  3  4  5 
f. History of undiagnosed vaginal bleeding  1  2  3  4  5 
g.Active liver disease  1  2  3  4  5 
h.Thromboembolic disorders  1  2  3  4  5 
i.Malignant Melanoma  1  2  3  4  5 
j.Other contraindications to ERT  1  2  3  4  5 
(please list): 97 
22.  Which, if any, of the following conditions would prevent you from prescribing
HRT?(circle one number for each of the following) 
very 
unlikely  unlikely  unsure  likely 
very I 
likely 
a. History of breast cancer in family  1  2  3  4  5 
b. History of scoliosis  1  2  3  4  5 
c. History of heart diseas  1  2  3  4  5 
d. History of hepatitis  1  2  3  4  5 
e. History of varicose veins  1  2  3  4  5 
f. History of high blood pressure  1  2  3  4  5 
g. History of hemolytic disease  1  2  3  4  5 
h. Allergic to pollen  1  2  3  4  5 
I. History of bone breaks  1  2  3  4  5 
j. Malignant Melanoma  1  2  3  4  5 
k.Other contraindications to HRT  1  2  3  4  5 
(please  list): 
23.The following statements are various treatments and protocols concerning 
menopause. How likely, unlikely, or unsure would you be about recommending each in 
your general practice? (Please circle one number for each ) 
very  very I 
unlikely  unlikely  unsure  likely  likely 
a.Suggest HRT to a woman recovering 
from a hysterectomy  1  2  3 
b.Place a woman on ERT when there is a history of 
breast cancer in the family  1  2  3 
c.Recommend calcium supplements to a 
menopausal woman  1  2  3 
d.Suggest/recommend naturopathic remedies 
to a woman presenting with early symptomology 
of menopause.  1  2  3 
e.Urge a menopausal women to make nutritional 
changes  1  2  3 
f.Help a menopausal woman structure a weight bearing 
exercise program  1  2  3 
g.Require a post menopausal women to stop 
smoking before you prescribe ERT  1  2  3 
h.Recommend a woman decreases her alcohol 
intake as part of her menopausal treatment program..1  2  3 
i.Discuss HRT options with a woman and help 
her weigh her individual risks and benefits  1  2  3 
j.Require a bone scan to assess whether ERT is 
necessary  1  2  3 
4  5 
4  5 
4  5 
4  5 
4  5 
4  5 
4  5 
4  5 
4  5 
4  5 98 
24.  How likely are you to prescribe...(circ/e one number for each) 
very 
unlikely  unlikely unsure  likely 
very
likely 
I 
a.ERT to a symptomatic menopausal 
client without contraindications?  1  2  3  4  5 
b.ERT to a symptomatic menopausal 
client with contraindications?  1  2  3  4  5 
c.HRT to a symptomatic menopausal 
client without contraindications?  1  2  3  4  5 
d.HRT to a symptomatic menopausal 
client with contraindications?  1  2  3  4  5 
25. Listed below are sentences about menopause.  (Please indicate level of agreement with 
each of the following statements by circling  one number for each statement) 
strongly  strongly
disagree disagree  uncertain  agree  agree 
a.Menopause is a metabolic and 
endocrine disorder  1  2  3  4  5 
b.One starts to feel old in the climacteric  1  2  3  4  5 
c.The benefits of HRT outweigh the risks  1  2  3  4  5 
d. Menopause is a process of normal aging  1  2  3  4  5 
e.Menopausal symptoms such as vasomotor 
instability, depression, anxiety, and headaches 
should be treated with hormone replacement 
therapy (HRT)  1  2  3  4  5 
f.One grows mature and more self-confident in 
menopause  1  2  3  4 5 
g.After menopause women have less 
sexual needs  1  2  3  4  5 
h.The absence of menstruation after 
menopause is a relief  1  2  3  4  5 
i.During menopause one often feels unwell....  1  2  3  4  5 
j.Menopause brings many positive aspects  1  2  3  4  5 
k.Menopause can be a time of personal growth 
for women  1  2  3  4 5 
1.A woman should consult her practitioner as 
soon as she suspects she is menopausal  1  2  3  4  5 
m.Women expecting complaints in menopause 
will get them  1  2  3  4  5 99 
The following questions will help us collect some general information 
about you. 
26.	  Are you Male or Female: 
1  MALE  2  FEMALE 
27.  What is your age?_  Years 
28.  Which one of the following best describes your ethnic orientation? 
1 ASIAN/PACIFIC ISLANDER  4 WHITE 
2 BLACK  5 NATIVE AMERICAN/ALASKAN NATIVE 
3 HISPANIC ORIGIN/LATINO  6 OTHER (please specify) 
29.  Are you (circle one number) : 
1  SINGLE/NEVER MARRIED  4  DIVORCED 
2  MARRIED  5  WIDOWED 
3  HAVE A LIVE-IN PARTNER 6  SEPARATED 
30.  On the back on this page, please briefly explain or list what was missing in 
your education in relation to menopause. 
PLEASE RETURN THIS SURVEY IN THE PRE-ADDRESSED
 
ENVELOP
 
BY  JULY 15,  1995
 
THANK YOU FOR TAKING YOUR VALUABLE TIME TO FILL OUT 
THIS QUESTIONNAIRE!! 100 
Appendix B: Qualitative Data 101 
Clinical  Years in 
specialty practice 
family  4 
Adult  10 
women  8 
Family  15 
Adult  14 
Adult  3 
Adult  14 
Family  1 
family  4 
family  4 
Women's  13 
Women's  20 
Family  1 
Family  8 
CNM  17 
Comments 
Review of all or most of research on risk vs. benefits 
of HRT +/or ERT and the constantly changing 
information. 
Emphasis on women having a choice and options re: 
use of HRT/ERT or other lifestyle changes to cope 
with. 
Medication use- protocol, various regiments, 
alternative- nutritional or homeopathic 
Naturopathic remedies and vitamins (e.g., vitamin E) 
Perimenopausal continuum, primary care for post 
womynstop. 
Alternatives to HRT 
Opinions regarding HRT have changed dramatically 
since my educational preparation, but basically, non 
pharmacological approaches were not described, 
specifically nutrition, exercise and supplements. 
Naturopathic approaches, complications of HRT. 
Any in-depth treatment. 
Naturopathic/homeopathic alternatives, exercise, 
nutrition, rest-general health issues, because of my 
age and feminism, I did research and a paper on this, 
as it was not covered. Women's health was not a 
required class. 
Full risk benefit discussion, alternatives to ERT/HRT. 
My education did not present any thing other than at 
the first sign of menopausal rx's start treatment. 
Case studies re: practical issues. Pro/Con ERT and 
HRT. Alternative TX menopause. 
We had very minimal educational offerings on 
menopause in my masters program 13 years ago. 
During my formal education there were 
misconceptions of this time. Lack of acceptance of 
menopause being a natural process, not a disease. 
Practical experience was missing. 
Missing from my education regarding menopause was 
a comprehensive approach to menopause, especially 
including alternative treatments. I do not believe 
menopause is a disease but I think many women think 
it is and are encouraged by the media and drug 
companies to. Like so much in my practice I think I 
will change my approach in this area once I 
experience it.  I think my training should have 
included more writings by women going through 
menopause- personal accounts. 
Non medication alternatives, clarification of risks vs. 
benefits, no education in HRT in basic program. 
Code 
3 
1,4 
1,5 
1 
6 
1, 7 
4 
1,6 
1, 15 
1, 2, 
3, 15 
8 
9 
2 
1, 4, 
5, 6, 7 
1, 8 102 
Adult  3  Naturopathic / herbal Rx for symptoms, management 
of HRT esp. initially and with irregular bleeding. 
Most of my knowledge came from self experience and 
reading. 
CNM  11  Physiology was only briefly covered and TX was not 
discussed as my certificate program in 1984 did not 
include it within the scope of practice of a CNM. 
Family  15  At the time of my training the concept of HRT had not 
been developed. 
Family  20  After 20 yr.. It is difficult to recall what was in 
program and what was obtained through experience 
or cont. ed. 
Adult  10  Alternative treatments, emotional reactions to 
menopause, latest research (controversial) Individual 
variations in response to menopause. 
CNM  5  I got a lecture in gynecological disorders and nothing 
at all on: 1) Physiology of 
perimenopause/menopause. 2) Physiological needs-
nutrition exercise 3) emotion/spiritual/ psychosocial 
changes that arise 4) regimes/protocols for TX/ 
endometrial biopsy etc.  I am still frustrated by the 
lack of consensus in literature and real lack of 
information regarding perimenopause. 
Women  3  What seemed most lacking in my formal education 
was treatment options and symptomology of peri 
menopause period i.e., 10 year (...?) The lack of 
clear research or naturopathic remedies is also lacking 
in medical education. 
CNM  15  Having trained in another country (Scotland), it 
wasn't ever part of our curriculum. All I have 
gathered is from article, conferences and workshops. 
In my practice the no of menopausal women is so 
small I send them to the MD if they are interested in 
HRT. 
Women  3  Natural Remedies for menopausal symptoms 
Women  20  My program was for family planning NP 20 years 
ago. 14 years ago I updated courses and qualified as 
a women's health NP and took the national certifying 
exam. Nothing was directed toward treating 
menopausal women. Since then I have attended 
conferences addressing these issues, done 
independent study and consulted other NPs. My 
practice is beginning to change as the population ages 
and these women are now presenting in the family 
planning clinic. No protocols are written for treating 
menopausal women with ERT and HRT. On 
occasion I have refilled an existing Rx or initiated 
therapy and consulting with NP in private practice. 
Geriatrics  9  Do not recall going into much detail about the older 
woman or possible benefits from HRT or ERT (as 
well as risks). 
1 
4,10 
11 
12 
1, 3, 
13 
10, 6, 
4, 8 
4, 5, 
1, 3 
8 
1 
8 
12, 15
 Family  15 
Family  missing 
data 
Family  5 
Women's  11 
Family  3 
Adult  8 
CNM  18 
Family  7 
Women's  15 
Family  4 
CNM  9 
CNM  16 
CNM  1 
Adult  20 
Adult  12 
Emotional aspects, Newer data on HRT and ERT. 
Education for all conditions is based on the need of 
the time. Many women are entering menopause, so 
there is a need. And I think practitioners cannot 
expect a basic educational program to meet all their 
needs. NP & MD and etc. need to continually 
educate themselves on the needs of their patient in 
order to be a good provider. It is a responsibility, 
Homeopathic/ natural pathic approaches. 
Specific regimens of ERT/HRT treatments. 
Naturopathic alternatives for women who desire this 
approach. 
Natural/ Herbal/ supplemental remedies 
Everything!! I don't believe menopause was 
discussed, either in class or preceptorshop. I felt 
totally inadequate in this area, but have done some 
reading & much discussion with MD colleagues to 
learn what I know now. I treat very few menopausal 
women, as I spend 99% of my time in a student 
health center, but do work occasionally at the primary 
care clinic which oversees our student health center. 
My education focused on women of childbearing age 
with minimal discussion of menopause. I do not feel 
comfortable with helping women assess the pros and 
cons of HRT since I have mixed feelings from all I've 
read or heard. 
Treatment of symptoms, prevention of complications. 
Very little covers premature menopause, cause and 
effect. 
Homeopathic/Naturopathic remedies 
We had very little education in menopause almost 
everything I know about it today, I've learned 
through self study- mostly journal articles and CME 
sessions or self-guided CME articles. I primarily 
follow prenatal patients so get very minimal clinical 
exposure. 
All never mentioned. 
Knowledgeable inf.. RX to alternative RX for 
menopause. Professors were all on HRT and loved 
it. 
When I went to school HRT and ERT or menopause 
was barely taught because I became a NP over 20 
years ago. 
Knowledge we now have about CV protection, 
osteoporosis compared to breast and endometrial 
cancer risk; knowledge or low dose ERT and HRT 
effects. Prev'ly using high dose unopposed Estrogen 
TX. 
103 
13 
1 
1, 4 
1 
8 
8 
4 
14 
1 
8 
8 
1 
11 
3 104 
Family  1	  Contraindications; ERT -for women who can't or 
won't tolerate provera, with a intact uterus; timing of 
starting how to Identify menopause; Isolated 
symptoms without laboratory or cessation of menses. 
i.e. only night sweats. 
Geriatric  15  Results of the Providence study on non-estrogen 
drugs that prevent bone loss. 
CNM  4	  Just about everything except: give everyone HRT, 
everyone needs more calcium, Wt. bearing exercise is 
beneficial , a few contraindications that were in the 
process of becoming not contraindications. I still 
often feel like I'm flying by the seat of my pants on 
this one. Wish I knew more about dosing, med. 
differences, natural remedies. Was taught/told 
(Speroff) that menopause is like a disease state that 
needs to be corrected. 
Adult  3	  Adequate focus and thoroughness of evaluating, 
diagnosing and treating menopause in general. 
Family  13  The trend at the time I went to school was no HRT/ 
ERT but no alternatives or even discussion occurred 
about menopause other than warning signs of 
endometrial cancer. 
Adult  11  Women's health was addressed very briefly. The 
same university now does an outstanding teaching 
presentation-
Family  12  Little attention to physiology/psychology of 
menopause- brief mention of ERT/HRT and calcium. 
No discussion of alternative remedies, exercise, 
recent research, etc. 
Missing  6  HRT vs. ERT; Calcium needs; Basic and essential 
management assessment skills and techniques; 
Alternative management; Pathophysiology; Aside 
from life cycles and aging, we were expected to seek 
our knowledge on own. 
Women's  16  More information on emotional psychological 
transitions; Best health care alternatives for those 
women refusing ERT/HRT; Strategies for managing 
patients with breakthrough bleeding on different HRT 
regimes. 
CNM  8  HRT; Extensive alternative treatments and natural 
remedies. 
Women's  2.5	  Additional clinical experience with mid-life women 
was the primary missing component. Also 
incontinence information/ assessment. 
OB/Gyn	  21  My program was brief, and did not have a lot on 
menopause. I have been able to get good inf.. from 
workshops, consults, and reading on my own. 
5, 7 
8 
4 
1, 8 
8 
1,3, 6 
10, 13 
1, 4, 
10, 7, 
15 
13, 1 
1 
2 
8 105 
Family  7  Alternative medications, diet, and exercise therapies, 
discussion of hormones, moods and diet 
relationships, risk of HRT; a risk vs. benefit approach 
to HRT; presentation of menopause as normal aging 
and positive aspects of personal growth during this 
time. 
Family  5	  Clinical exposure to menopausal women. 
CNM  5.5	  It was all there in theory but had very little clinical 
practice with menopausal women. 
Family  1	  1) HRT vs. ERT when is it appropriate to Rx ERT in 
a women with a uterus. My feeling is never given the 
propensity for endometrial hyperplasia and increased 
risk endometrial. cancer. Yearly biopsies seem to me 
to be an unnecessary risk when HRT is available. 
2) Use of naturally occurring estrogen/ progesterone. 
Friends who are ND's often speak of alternative 
methods which certainly have some credence but are 
not recognized secondary lack of adequate controlled 
studies/trials. These avenues should be explored & 
presented to NP students in order to allow for 
comprehensive primary care to women who utilize 
alternative practitioners as well as allopathic 
providers. 
Family  3	  It was not addressed .. in 15 min. lecture. The 
reproductive health course at OHSU at the time for 
FNP was a disaster with an incompetent teacher. I've 
been to many CE events and read intensively in this 
area so I feel essentially self taught in this arena of my 
practice. 
Family  3	  Didn't cover dosage/dosing options in enough depth 
and how to manage minor complications. Mostly 
medical model presented. 
Women's  3	  Very little Menopause focus 
Family  7	  Very little information about nutrition and exercise 
during menopause. 
Gyne- 22	  When I had my NP training in WH Care (1973) most 
cology	  of the emphasis was placed on gyn visits, 
contraception, and prenatal care. Women may live 40 
yr. after menopause, and there was not much 
education re: menopausal state. Most of my 
menopause education has been learned at continuing 
education meetings. This role of health care and 
preventive health for female over 45 has grown in my 
practice and should now be an equal part of the 
educational NP program. 
Adult  1	  Peri menopausal treatment options and in depth 
physical emotional accompanying effects of 
menopause. 
Family  23	  All the things we've learned in the past 20 years. 
1, 6, 
15, 9 
2 
2 
15, 1 
8 
4 
8 
6 
8 
5, 13 
11 106 
Family  15  Comfort measures for menopausal women who do 
not want to take HRT and the same for women whom 
HRT is contraindicated. 
Women  3  HRT/ ERT and liver problems 
Women  13  Alternative therapies with menopausal- more non-
biased approach to HRT and ERT. 
Adult  4  How to educate the patient on the risks vs. benefits of 
HRT/ERT. Naturopathic remedies or alternatives to 
HRT/ERT. The different types and strengths of 
estrogen, i.e.- creams vs. by mouth med.. vs. 
patches; premarin vs. others. In reality, I learned 
more about menopause treatment in my 
internship/preceptorship than in the classroom 
(didactic educ.). 
Adult  17  Naturopathic Remedies 
CNM  12  Alternative therapies i.e.- botanical support, natural 
progesterone/estrogen creams. 
CNM  6  The ACNM was just having dialogue with the Am. 
College of OB/GYN re: CNM's scope of practice as it 
pertained to managing women through menopause. 
Since it was not within midwifery scope of practice @ 
that time extensive discussion of menopause signs, 
symptoms and treatments was not presented. I feel 
the lack of inf.. now but have many MD's and NP's 
available to me in clinic for consultation. 
Adult  11  Basic education provides basics of physiology of 
menopause. conferences, in services have provided 
further inf. regarding prescribing estrogen, 
contraindications. The field changes constantly form 
one day to nest re: current recommendations therapy. 
I have excellent access to OB/GYN consult. 
Adult  16  No other Rx options suggested; no nutrition needs 
addressed. 
Clinical  2  My education at U of P missed the boat on HRT we 
research  had one class 1 hour describing basics- It was not 
until I went to an internal Med. review course at 
Providence Hospital that I learned scientific data 
results and recommended treatment. 
Family  2  I am basically a believer in HRT/ ERT but am 
uncertain about when to start it and /or how long to 
keep women on it.  ( this seems to be the current 
question). I have also read Susan Weed's book on 
menopause, which is totally about herbs, 
homeopathy, etc. and anti-establishment. 
CNM  24  The orientation of 1972 OBGYN NP program was 
women of child bearing age - menopause was only 
briefly mentioned. Same for 1977-79 CNM program-
mostly pregnancy- some childbearing age i.e.- family 
planning and some gyn problems. 
I 
7 
1 
1, 16 
1 
1 
8 
1, 6 
8 
4 
11 107 
CNM  12 
Family  11
 
Family  20
 
Family  15
 
Women  20
 
CNM  7
 
Family  2
 
Family  1 
Family  20
 
CNM  14
 
CNM  2
 
Family  8
 
CNM  11 
Geriatrics  2 
CNM  11 
8 
I've been in several different kinds of practice settings 
Not a lot compared to most NPs or family doctors­
- learned a lot in 12 years. 
Minimal experience as the token male in my program.  2 
20 yr. ago HRT was unknown and ERT had serious  11 
bad press. There was no medical consensus and most 
women were unwilling to take ERT.  My program 
tried to lay out the facts, buy there was so much 
confusion not specific recommendations could be 
make. The way I treat menopause now was learned 
after school. 
Current research findings on positive aspects of HRT.  3 
My education has been a process of being a NP for 20  13 
years and growing with and older with women 
friends and patients. I still don't know enough about 
the emotional impact, both positive and negative. I do 
know women want to be involved in decisions about 
their health. To be considered unique and not put on 
a standard protocol but to take into consideration their 
health, nutrition, physical actuity, family, mental 
health and spiritual health before making their 
informed decision with my assistance (as needed) for 
HRT and ERT. 
Basic inf.. about ERT and HRT dosages, etc.  4 
Missing- reasons to perform endometrial biopsy  8 
during menopausal changes. Inf. also was a little too 
general- not enough time to adequately cover inf.. 
It was very thorough for a FNP program. I could 
probably gauge it better if I had women in my 
practice. 
Interested in non-traditional natural remedies and  1 
ideas 
Almost everything/ one year program --no time for  8 
menopause. 
Practical experience with prescribing and educating  1, 2 
patients. Alternative therapies. 
Naturopathic treatment alternatives to HRT/ERT.  1 
I don't remember any menopausal component to my  8 
Yale CNM education. I think perhaps then (early 
80's) CNM's hadn't moved into menopausal mgmt. 
yet. 
Women's health course content was optional. I think  8 
this content should be expanded and required as 
women seek female NP's for this health care area. 
Note- most of my patients are elderly with dementia, 
so limited prescribing of HRT. 
We reviewed the physiology, but did not learn  4 
management at all. This was not considered part of a 
basic nurse- midwifery curriculum in the early 
1980's. 108 
Family  18  Comprehensive evaluation and Rx and management 
of the perimenopause. 
Adult  10  My educational tract 10 years ago did not teach HRT. 
Adult  6  Little inf.. given during my graduate program. 
Disease focus rather than focus on normal physiologic 
changes. 
CNM  4  My education covered many aspects of menopause 
both medical management and homeopathic 
management. My practice however is almost 
exclusively limited to women in childbearing years. 
missing  missing  Alternative therapies for HRT using herbs, tinctures, 
and teas. 
Geriatric  8  As a geriatric NP we were taught about post 
menopausal women an really nothing much about 
menopause. 
CNM  9  Everything except the fact that it occurs and standard 
ERT and HRT Rx. 
CNM  3  I had an extremely brief (one lecture)  needed more 
about alternatives, how to actually prescribe. 
Family  15  My basic FNP training was in 79-80. It is difficult to 
remember how adequate I felt my preparation was. I 
feel more importantly I developed critical thinking 
skills to help me evaluate and apply new data to the 
existing foundation. I believe you learn for your 
worksite and use a combination of sources to learn 
more. 
Adult  6  Very little was covered. 
CNM  26  Everything. 
Codes: 
1  alternative therapies 
2  lack of practical experience 
3  review of research 
4  protocol, regiments of HRT 
5  perimenopausal continuum 
6  nonpharmacological approaches-exercise, nutrition 
7  complications to HRT 
8  lack of education offerings/classes or only minimum offered. 
9  lack of acceptance of menopause being a natural process 
10  physiology 
11  HRT not developed 
12  difficult to recall what was in or not 
13  psychosocial changes 
14  cause of premature menopause 
15  risk vs. benefit of HRT/ERT 
16  how to educate re: risk vs. benefit of HRT/ERT 
4 
8 
8, 9 
1 
8 
8 
8 
12 
8 
8 109 
Appendix C: Additional Results 110 
Research Question #6: 
What is the relationship between nurse practitioners' attitudes about menopause 
and their likelihood of prescribing either HRT or ERT? 
Analysis of this question consisted of Spearman correlation coefficient. The 
following tables show the numbers of subjects who answered the likelihood of 
prescribing questions and their corresponding attitudes about menopause. 
Table C.1 ERT w/o contraindications vs. Attitudes about menopause 
SPEARMAN CORRELATION 
ERT W/O  VALUE  P VALUE  VALID	  DEGREES OF 
FREEDOM CONTRAINDICATIONS	  SIGNIFICANCE  CASES 
METABOLIC DISORDER  .068  .371  173  171 
ONE STARTS TO FEEL OLD  -.006  .937  176  174 
*BENEFITS OF HRT OUTWEIGH  .332  .000  178  176 
RISKS 
MENOPAUSE IS A PROCESS OF  .091  .222  180  178 
NORMAL AGING 
*MENOPAUSAL SYMPTOMS  .237  .001  178  176 
SHOULD BE TREATED WITH HRT 
ONE GROWS MATURE AND MORE  .089  .241  175  173 
CONFIDENT IN MENOPAUSE 
AFTER MENOPAUSE WOMEN HAVE  -.043  .546  180  178 
LESS SEXUAL NEEDS 
*ABSENCE OF MENSTRUATION IS  .212  .005  176  174 
A RELIEF 
DURING MENOPAUSE ONE OFTEN  -.123  .106  175  173 
FEELS UNWELL 
*MENOPAUSE BRINGS MANY  .173  .021  179  177 
POSITIVE ASPECTS 
MENOPAUSE CAN BE A TIME OF  .108  .150  180  178 
PERSONAL GROWTH 
*WOMEN SHOULD CONSULT HER  .183  .014  179  177 
PRACITIIONER WHEN SHE 
SUSPECTS SHE IS MENOPAUSAL 
WOMEN EXPECTING COMPLAINTS  .114  .130  177  175 
IN MENOPAUSE WILL GET THEM 
Significant associations were apparent for five of the above statements. Nurse 
practitioners who agreed with the statement "The benefits of HRT outweigh the risks" 111 
were more likely to prescribe ERT when contraindications were not present.  This 
association is practical and make sense. The population of nurse practitioners who felt 
that HRT benefits outweigh the risks would be more likely to prescribe ERT. An 
association between the statement "Menopausal symptoms such as vasomotor instability, 
depression, anxiety, and headaches should be treated with hormone replacement therapy" 
and prescribing ERT was positive. Nurse practitioners who felt that symptoms should 
be treated were those who were most likely to prescribe ERT when contraindications 
were not present. 
There was an association between those who agreed with the statement "The 
absence of menstruation after menopause is a relief' and the likelihood of prescribing 
ERT when contraindications were not present. This association is not a "practical" or 
understandable one to this researcher. 
An association between the statement "Menopause brings many positive aspects" 
and the likelihood of prescribing ERT when contraindications were not present. This 
association is interesting and not altogether understandable. If menopause brings many 
positive aspects, why should a women go on ERT? Is this so morbidity (osteoporosis 
and CHD) will be reduced so that the menopausal woman can enjoy her life? Table C.1 
lists the results. 
In Table C.2, the Spearman correlations between attitudes about menopause and 
the likelihood of prescribing ERT when contraindications are present are shown. Only 
two associations were statistically significant and warrant any mentioning. Those who 
disagreed with the statement "Menopause is a metabolic and endocrine disorder" were 
less likely to prescribe ERT when contraindications were present. This associations is 
common sense. Nurse practitioners who think that menopause is a part of normal aging 
are less likely to prescribe ERT, particularly when contraindications are present. Along 
the same vein was the statement "One starts to feel old in the climacteric." Practitioners 112 
who disagreed with this statement were less likely to prescribe ERT when 
contraindications were present. Perhaps NP's who felt that the statement was a ageist 
statement were less likely to prescribe a drug which is associated with being older. 
Table C.2 ERT with contraindications vs. Attitudes about menopause 
SPEARMAN CORRELATION 
ERT WITH  VALUE  P VALUE  VALID  DEGREES OF 
CONTRAINDICATIONS  SIGNIFICANCE  CASES  FREEDOM 
*METABOLIC DISORDER  .174  .022  174  172 
*ONE STARTS TO FEEL OLD  .163  .031  176  174 
BENEFITS OF HRT OUTWEIGH  .128  .089  178  176 
RISKS 
MENOPAUSE IS A PROCESS OF  -.112  .134  180  178 
NORMAL AGING 
MENOPAUSAL SYMPTOMS  -.058  .441  178  176 
SHOULD BE TREATED WITH HRT 
ONE GROWS MATURE AND MORE  -.036  .637  175  173 
CONFIDENT IN MENOPAUSE 
AFTER MENOPAUSE WOMEN HAVE  -.004  .953  180  178 
LESS SEXUAL NEEDS 
ABSENCE OF MENSTRUATION IS A  -.075  .322  176  174 
RELIEF 
DURING MENOPAUSE ONE OFTEN  .100  .189  175  173 
FEELS UNWELL 
MENOPAUSE BRINGS MANY  -.136  .069  179  177 
POSITIVE ASPECTS 
MENOPAUSE CAN BE A TIME OF  -.108  .150  180  178 
PERSONAL GROWTH 
WOMEN SHOULD CONSULT HER  .006  .932  179  177 
PRACtIfIONER WHEN SHE 
SUSPECTS SHE IS MENOPAUSAL 
WOMEN EXPECTING COMPLAINTS  .042  .580  177  175 
IN MENOPAUSE WIT .1 GET THEM 
Table C.3 lists the Spearman correlation coefficients for the variables attitudes 
about menopause and likelihood of prescribing HRT when contraindications were not 
present. Agreement with three of the statements were highly associated with prescribing 
HRT when contraindications were not present. The statements were: 113 
The benefits of HRT outweigh the risks
 
Menopausal symptoms such as vasomotro instability, depression, anxiety, and
 
headaches shoul be treated with HRT.
 
A woman should consult her practitioner as soon as she suspects she is menopausal.
 
Table C.3 1-1RT w/o contraindications vs. Attitudes about menopause 
SPEARMAN CORRELATION 
P VALUE  VALID  DEGREES OF HRT W/O  VALUE 
CONTRAINDICATIONS  SIGNIFICANCE  CASES  FREEDOM 
.101  .186  173  171 METABOLIC DISORDER 
175  173 ONE STARTS TO FEEL OLD  -.035  .642 
*BENEFITS OF HRT OUTWEIGH  .464  .000  177 
RISKS 
MENOPAUSE IS A PROCESS OF  .143  .057  179  177 
NORMAL AGING 
*MENOPAUSAL SYMPTOMS  .370  .000  177  175 
SHOULD BE TREATED WITH HRT 
ONE GROWS MATURE AND MORE  .079  .301  174  172 
CONFIDENT IN MENOPAUSE 
AHER MENOPAUSE WOMEN HAVE  -.120  .111  179  177 
LESS SEXUAL NEEDS 
ABSENCE OF MENSTRUATION IS A  .135  .075  175  173 
RELIEF 
DURING MENOPAUSE ONE OF EN  -.036  .639  174  172 
FEELS UNWELL 
*MENOPAUSE BRINGS MANY  .172  .022  178  176 
POSITIVE ASPECTS 
*MENOPAUSE CAN BE A TIME OF  .202  .007  179  177 
PERSONAL GROWTH 
*WOMEN SHOULD CONSULT HER  .276  .000  178  176 
PRACin ION'ER WHEN SHE 
SUSPECTS SHE IS MENOPAUSAL 
WOMEN EXPECTING COMPLAINTS  .071  .352  176  174 
IN MENOPAUSE W11.1. GET THEM 
The correlation coefficients were .464, .370, and .276, respectively. Nurse 
practitioners who agreed with these three statements were highly likely to prescribe HRT 
when contraindications were not present. Also associated with prescribing HRT were 
the statements "Menopause brings many positive aspects" and "Menopause can be a time 
of personal growth." More attitudinal statements were positively associated with 
prescribing HRT than any of the four possible prescribing practices. 114 
Table C.4 HRT with contraindications vs. Attitudes about menopause 
SPEARMAN CORRELATION 
HRT WITH  VALUE  P VALUE/  VALID  DEGREES OF 
CASES  FREEDOM CONTRAINDICATIONS  SIGNIFICANCE 
171 METABOLIC DISORDER  .048  .527  173 
*ONE STARTS TO FEEL OLD  .176  .020  175  173 
BENEFITS OF HRT OUTWEIGH  .139  .065  177  175 
RISKS 
*MENOPAUSE IS A PROCESS OF  -.187  .012  179  177 
NORMAL AGING 
MENOPAUSAL SYMPTOMS  .064  .395  177  175 
SHOULD BE TREATED WITH HRT 
ONE GROWS MATURE AND MORE  -.035  .651  174  172 
CONFIDENT IN MENOPAUSE 
Al- IER MENOPAUSE WOMEN HAVE  -.024  .754  179  177 
LESS SEXUAL NEEDS 
*ABSENCE OF MENSTRUATION IS  -.157  .038  175  173 
A RELIEF 
DURING MENOPAUSE ONE OFTEN .122  .110  174  172 EN 
FEELS UNWELL 
MENOPAUSE BRINGS MANY  -.140  .062  178  176 
POSITIVE ASPECTS 
MENOPAUSE CAN BE A TIME OF  -.083  .269  179  177 
PERSONAL GROWTH 
WOMEN SHOULD CONSULT HER  .026  .729  178  176 
PRAC1I IIONER WHEN SHE 
SUSPECTS SHE IS MENOPAUSAL 
WOMEN EXPECTING COMPLAINTS  -.048  .523  176  174 
IN MENOPAUSE WIT I . GET THEM 
When contraindications were present the associations between prescribing HRT 
and attitudes became negative in nature, except for one significant association. Nurse 
practitioners who agreed with the statement that "One feels old in the cliamacteric" were 
also more likely to prescribe HRT when contraindications were present. Those nurse 
practitioners who agreed with the statement "Menopause is a process of normal aging" 
were less likely to prescribe HRT when contraindications were present. Also, nurse 
practitioners who agreed with the statement "Absence of menstruation is a relief' were 
less likely to prescribe HRT. 115 
Ideally, a larger sample size of nurse practitioners would increase significance of 
many of the associations. Overall, attitudes were not highly associated with likelihood of 
prescribing any of the four possible combinations. 
Research Question #7: 
Is there a difference between nurse practitioner's perceived adequacy of formal 
education in menopausal issues and likelihood of prescribing either ERT or HRT? 
Analyzes of this research question consisted on the Mann-Whitney test, which is 
a method of inference for an ordinal dependent variable and a nominal independent 
variable. It is a nonparametric test which is often substituted for the Student's t test. 
There was no significant difference found between nurse practitioner's perceived 
adequacy of formal education in menopausal issues and likelihood of prescribing either 
ERT or HRT. 